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CHAPTER I
INTRODUCTION AND BACKGROUND
The human placenta is one of the most important organs in the human body for the health
of both the woman and her fetus during pregnancy, and is at the same time one of the least
understood [1]. The role of the placenta is not confined to the health of the fetus during
pregnancy, but also impacts its long-term health into adult life [2, 3]. Abnormal placental
function can lead to pregnancy diseases that can adversely effect both the fetus and the mother,
such as preeclampsia (PE), intrauterine growth restriction (IUGR), preterm labor (PTL), and
early pregnancy loss (EPL) [4-6]. A crucial process during placentation is the differentiation of a
subset trophoblast cells in the anchoring villi into an extravillous, invasive phenotype during the
first trimester. Extravillous trophoblast (EVT) cells, migrate through the decidua, into the
superficial layer of the myometrium, and remodel the smooth muscle of the maternal uterine
spiral arteries [7]. Remodeling of the uterine spiral arteries transforms narrow, high-resistance
blood vessels into dilated, low-resistance conduits of maternal blood into the intervillous space
of the placenta [8]. Failure of the EVT cells to invade into the myometrium early in pregnancy
can lead to uteroplacental insufficiency, and result in pregnancy complications such as PE,
IUGR, and EPL [6, 9-11].
Prior to 10 weeks gestation, EVT cells migrate into the uterine spiral arteries and form an
endovascular plug, occluding the arteries, and thereby limiting maternal blood flow to the
intervillous space of the placenta [12].

This necessary step creates a relatively hypoxic

environment with the pO2 < 20mmHg at 8-10 weeks, which is 2-3 times lower than the values of
>50mmHg found after 12 weeks gestation [13, 14]. The reduced oxygen environment promotes
trophoblast proliferation [15], and protects trophoblast cells from oxidative stress as levels of
antioxidants and enzymes necessary to prevent oxidative damage are lowest in first trimester
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placenta [16-18]. In vitro studies reveal that first trimester cytotrophoblast cells are damaged
after exposure to hypoxia/reoxygenation, which mimics the premature onset of blood flow [19].
In vivo studies reveal a clear link between premature placental blood flow and EPL [12, 20, 21].
The ability of EVT cells to invade maternal tissue, proliferate, and remodel the spiral
arteries depends on complex interactions between trophoblast cells and the endometrium. A
family of proteins that are essential for trophoblast-uterine interactions is the epidermal growth
factor (EGF) signaling system, which includes heparin-binding EGF-like growth factor
(HBEGF), transforming growth factor-alpha (TGFA), amphiregulin (AREG), betacellulin
(BTC), and epiregulin (EREG) [22]. The EGF-like growth factors activate receptor tyrosine
kinases in the plasma membrane that include epidermal growth factor receptor (EGFR/ERBB1)
and related ERBB family proteins (ERBB2, ERBB3, ERBB4). Growth factor binding initiates
an intrinsic protein-tyrosine kinase activity, autophosphorylation of the cytoplasmic domain and
receptor dimerization to generate a downstream signaling cascade [23]. HBEGF is regulated
independently of the presence of an embryo during the menstrual cycle of the human
endometrium [24, 25], indicating its preparatory role for implantation. HBEGF is also highly
critical for healthy placental development, as strong HBEGF staining is observed in villous and
extravillous trophoblast cells [25, 26]. HBEGF and other members of the EGF family promote
trophoblast invasion and extravillous differentiation [27-29]. HBEGF likely plays a protective
role for trophoblast cells in a hypoxic environment, as HBEGF is upregulated by hypoxia [30].
Decreased placental HBEGF expression has been linked to placenta-mediated disorders such as
PE [26].
PE is a hypertensive obstetric disease that affects 2%-8% of all pregnancies, is one of the
leading causes of maternal morbidity and mortality, and is responsible annually for
approximately 50,000 deaths worldwide [9, 31].

PE is generally defined as new onset
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hypertension and proteinuria at or after 20 weeks gestation [32]. PE is a multi-organ vascular
disease with complications that produce major morbidities, including kidney failure,
cerebrovascular bleeding, seizures, liver damage, hemolysis, thrombocytopenia, and placental
abruption [9]. The risks of PE are not confined to the mother, as risks to the fetus include IUGR,
poor oxygenation, and complications arising from preterm delivery [33]. IUGR is defined as an
estimated fetal weight less than the 10th percentile for gestational age, and itself is a pregnancy
disorder often related to abnormal placentation [34]. The burden of IUGR is not confined to the
fetus and neonate, as babies born with IUGR often have adverse long-term health consequences
into adulthood [35, 36]. Both PE and IUGR share similar pathophysiologies in that there is
abnormal myometrial spiral artery remodeling due to abnormal trophoblast invasion [4].
EPL, also known as miscarriage, is one of the most frequent complications that occur
during pregnancy. The rate of EPL prior to implantation is estimated to be up to 40%, with
clinically recognized miscarriages occurring in approximately 15% of pregnancies [37].
Recurrent EPL, defined as three or more consecutive miscarriages, occur in approximately 1% to
3% of couples trying to conceive [38, 39]. It has been suggested that oxidative stress in the first
and second trimester, in part due to abnormal trophoblast invasion, is responsible for EPL, with
approximately two thirds of early pregnancy failures revealing evidence of defective placentation
[6, 40].
Early prediction of PE and IUGR would allow for close monitoring of patients at risk,
improve the design of trials for preventive strategies, and reduce health care expenditures for
pregnancies determined to not be at risk. Unfortunately, there are no reliable tests to preclinically detect PE, IUGR, and EPL [41]. Multiple methods have been evaluated, including
serum biomarker and ultrasound Doppler assessment. However, no single test has proven to be
clinically useful in predicting pregnancies that will develop PE or IUGR [42]. One of the rate-
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limiting steps is the inability obtain intact placental cells or EVT cells from ongoing pregnancies
in a minimally-invasive fashion. The Armant laboratory, as will be described in this dissertation,
has developed an innovative method to obtain EVT cells from ongoing pregnancies as early as 5
weeks gestation in a minimally-invasive approach, thereby allowing for the first time cellular and
molecular assessment of placental function in real time.
Clinical interest in obtaining placental tissue from ongoing pregnancies is not limited to
the health of pregnancy, but could also provide a method for prenatal genetic diagnosis (PGD).
The risk of having a newborn with a chromosomal abnormality or structural abnormality is
approximately 3%-5% [43]. Diagnosis of chromosomal abnormalities requires obtaining fetal
tissue.

The most common methods for PGD involve amniocentesis and chorionic villous

sampling (CVS). Amniocentesis, or trans-uterine aspiration of secreted amniocytes or fetal cells,
is generally preformed between 15 and 20 weeks gestation. CVS involves obtaining placental
villi transcervically or transabdominally after 10 weeks gestation. Both methods are invasive,
and carry a fetal loss rate of approximately 0.5%-1.0%, even in experienced hands [44].
Recently, non-invasive prenatal testing (NIPT) using cell-free fetal DNA has become a widely
available method of prenatal genetic testing. Maternal plasma cell-free fetal DNA is thought to
be derived from the placenta, comprises approximately 3%-13% of total cell free DNA in
maternal plasma, and is currently offered to identify fetuses with aneuploidies in chromosomes
13, 18, 21, X, and Y, with a slightly lower sensitivity for chromosome 13 compared to
chromosomes 18 and 21 [45-47].

Despite its clinical usefulness, NIPT is not without its

limitations. Current clinical guidelines consider this method to be a form of genetic screening,
requiring that abnormal results be confirmed by an invasive test such as CVS or amniocentesis
[48]. Furthermore, NIPT is only recommended for pregnancies at high risk for aneuploidy, the
earliest it is currently offered is 10 weeks GA, and it relies on cell free DNA, as opposed to intact
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fetal cells, which limits its screening capabilities [48]. Therefore, a non-invasive alternative to
NIPT that can isolate intact fetal cells and be performed earlier than 10 weeks gestation is
warranted.
It has been shown that as early as 5 weeks gestation, trophoblast cells shed into the lower
uterine segment and can be retrieved from the uterus or cervix in ongoing pregnancies by various
methods [49]. The first report identifying placental cells in the cervix of ongoing pregnancies
was reported in 1971 by Landrum Shettles [50]. In his landmark paper, he reported that in
mucus obtained with a cervical cotton swab he found cells staining for the Y body. In a handful
of the corresponding patients, a male fetus was delivered. Subsequently, many investigators
identified trophoblast cells from pregnant patients, using aspiration of cervical mucous with a
catheter [51-53] endometrial biopsy [54], endocervical canal lavage [55, 56], and uterine cavity
lavage [57], and with success rates ranging between 50% -95%. Perhaps the least invasive and
most successful method was with a cytobrush, similar to the Papanicolaou test, with a success
rate of 95% [58]. Furthermore, use of a cytobrush during pregnancy has proven to be safe
according to multiple investigators [59-62].
Trophoblast cells obtained from the cervix of pregnant patients have been evaluated for
prenatal genetic diagnosis. They have been used in the detection of trisomies 18 and 21 in
fetuses with known aneuploidies [63-65], Rh fetal status in Rh negative mothers [66], and even
hemoglobinopathies [67].

Despite these promising findings, their use in prenatal genetic

diagnosis is limited by the inability to efficiently isolate trophoblast cells in specimens
containing many-fold more maternal cells. By immunocytochemistry (ICC), it was deduced that
the ratio of trophoblast cells to maternal cells is approximately 1 in 2000 [58]. Recently,
transcervical retrieval and isolation from the cervix (TRIC), a novel approach to efficiently
isolate trophoblast cells by immunomagnetic isolation using nanoparticles coupled to
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monoclonal antibodies against human leukocyte antigen-G (HLA-G) was introduced [68] (Figure
1). HLA-G is a class 1b major histocompatability complex (MHC) protein that is not expressed
by maternal cervical cells, but is upregulated in cytotrophoblast cells as they differentiate into the
invasive EVT phenotype [69]. It is involved in immune tolerance at the maternal-fetal interface
[69].

Figure 1: TRIC Procedure. Endocervical specimens obtained at 5-20 weeks gestational age are
fixed in transport medium, and EVT cells (red) are isolated, using immunomagnetic separation.
Isolated EVT cells are archived mounted on slides or frozen in PCR tubes.
Trophoblast cells can be isolated by TRIC with purity as high as 99% between 5 and 20
weeks gestation [68]. According to protein expression patterns, the isolated cells appeared to be
of the extravillous phenotype. The cells contain intact nuclear DNA, as evidenced by terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) [68]. Furthermore, TRIC was
used to correctly identify gender by both the polymerase chain reaction (PCR) and fluorescence
in situ hybridization (FISH).
The ability of TRIC to isolate intact EVT cells from pregnancies in a minimally-invasive
approach using endocervical specimens collected as early as 5 weeks gestation provides an
opportunity to develop an alternative to NIPT for PGD. However, some studies suggested that
trophoblast cells exhibit a high degree of aneuploidy as they differentiate into the invasive
phenotype [70, 71]. Prior to evaluating TRIC as a method for PGD, we must establish whether
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EVT cells obtained by TRIC exhibit a high degree of aneuploidy. TRIC not only holds promise
for PGD, but could also provide a non-invasive method for “real-time’” assessment of placental
function.
It is well established that uterine-trophoblast communication is essential for healthy
placentation, and for the health of the fetus and mother, both intra- and post-partum. The
objective of my dissertation is three fold. First, we hypothesize that the EGF family of proteins
is dysregulated in placentas from patients with PE, based on a previous finding that HBEGF is
highly downregulated in placentas delivered by women with PE [26]. To test this hypothesis, we
will evaluate the EGF family of proteins in post-partum placentas and perinatal serum from
patients with confirmed PE, alongside gestational age (GA) matched non-PE patients. The
second objective is to evaluate protein expression patterns in EVT cells obtained by TRIC from
pregnancies with adverse and uncomplicated term outcomes. We hypothesize that EVT cells
obtained by TRIC between 5 and 20 weeks GA will reveal dysregulated protein signatures in
pregnancies that later develop PE, IUGR, and EPL, compared to uncomplicated term
pregnancies. To test this hypothesis, we will evaluate by ICC the expression of seven proteins
known to play a role in EVT function in each cohort of patients. Lastly, we hypothesize that
EVT cells obtained by TRIC exhibit low levels of mosaicism. To test this hypothesis, we will
use fluorescence in situ hybridization (FISH), to evaluate the ploidy of EVT cells obtained by
TRIC for chromosomes 13, 18, 21, X, and Y. This investigation will demonstrate the prognostic
value of EVT cells obtained non-invasively in the first half of pregnancy.
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CHAPTER II
REDUCED EXPRESSION OF THE EPIDERMAL GROWTH FACTOR SIGNALING
SYSTEM IN PREECLAMPSIA
(This chapter contains previously published material. See Appendix B).
Introduction
Approximately 5% of human pregnancies are complicated by preeclampsia (PE), which
is one of the leading causes of neonatal and maternal deaths in developed countries [72]. The
syndrome is clinically defined by the presence of maternal hypertension and proteinuria
occurring after 20 weeks of pregnancy in a previously normotensive, non-proteinuric patient
[73]. Although the etiology of this condition is poorly understood, strong evidence supports
involvement of deficient trophoblast survival, inadequate endovascular invasion, endothelial cell
dysfunction and a systemic maternal inflammatory response [74-80]. Thus, events that occur
during early placentation compromising trophoblast function could predispose to PE, while
conditions arising much later in gestation exacerbate the onset of disease.
Accumulating evidence suggests that human trophoblast survival and invasive capacity
are linked to intercellular signaling by peptides related to EGF.

EGF can protect against

apoptosis induced during in vitro culture of human term cytotrophoblast cells [81, 82], indicative
of the ability of EGF and related proteins to act as survival factors. Peptide members of the EGF
signaling system induce downstream signaling by binding to receptor tyrosine kinases of the
EGFR/ERBB family, which contains four members [23, 83].

Trophoblast motility and

invasiveness are stimulated by EGF, TGFA and HBEGF, based on in vitro studies of first
trimester primary and immortalized cytotrophoblast cells [84]. HBEGF induction of extravillous
trophoblast differentiation can be mediated by either EGFR/ERBB1 or ERBB4 [29]. HBEGF
also protects first trimester cytotrophoblast cells from apoptosis when they are exposed to low
concentrations of O2 [30] or oxidative stress due to hypoxia/reoxygenation (H/R) injury [19].
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Since preeclampsia is associated with failed trophoblast survival and invasive function [74, 75,
77], it is noteworthy that HBEGF expression is significantly reduced in the placentas of women
with preeclampsia [26].
In addition to EGF, TGFA and HBEGF, the EGF family includes BTC, AREG and
EREG [23, 83]. A truncated EGFR/ERBB1 isoform (p110/EGFR) has been identified and is
elevated in PE patients [85]. Because p110/EGFR lacks the cytoplasmic domain, it could act as
a dominant negative, adding to the complexity of this biochemical network.
Since the EGF signaling system includes several growth factors capable of regulating
human trophoblast survival and invasiveness, including HBEGF, which is downregulated in
trophoblast cells from the placentas of women with PE, we hypothesized that members of the
EGF family of peptides, in addition to HBEGF, and the p110/EGFR splice variant are
dysregulated in placentas of women with PE. Similar outcomes in placentas can be found in
conjunction with small for gestational age (SGA) infants. To compare for GA, placentas from
women with PTL without evidence of PE, SGA, or infection were evaluated, and to compare for
PTL, normal placentas delivered at term were evaluated. Because components of the EGF
signaling system have been shown to reduce apoptosis in human trophoblast cells, EGF family
members were compared for their ability to rescue trophoblast cells from apoptosis after H/R
injury. Finally, we examined the hypothesis that EGF-like growth factors that are dysregulated
by PE in the placenta are similarly altered in the circulation of patients with PE.
Materials and Methods
Patient population
The Institutional Review Board of Wayne State University approved all consent forms
and protocols used in this study, which abide by the NIH research guidelines. Placentas were
obtained from pregnancies with: 1) PE (n=35, mean GA=31.8 weeks, SD=3.8), defined as the
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presence of hypertension, proteinuria (+2) and delivery before the 35th week of gestation in
nulliparous (n=19) or multiparous (n=16) women; 2) SGA infants without PE (n=17, mean
GA=33.2 weeks, SD= 3.6), defined as a birth weight below the 10th percentile and without
anomalies; and 3) spontaneous PTL leading to preterm delivery (n=17, mean GA=32.4 weeks,
SD=3.5) without histological chorioamnionitis. Tissues from patients with PE, SGA, or PTL of
similar GA (19–35 weeks) were compared at the time of delivery. There were no significant
differences in GA among the three patient groups. Additional placentas were obtained from
patients with uncomplicated pregnancies delivering at term (n=7, mean GA=39.2 weeks, SD=
0.3). The smaller N of the term group reflects the narrower range of GA compared to PTL.
P110/EGFR staining was compared amongst PE (n=29, mean GA= 31.3, SD = 3.2), SGA (n=
13, mean GA= 32.0, SD= 3.3), PTL (n= 10, mean GA= 31.4, SD= 3.9), term (n= 6, mean= 38.3,
SD= 1.0). Placental tissues were selected from a large pool of archived tissues, based on patient
inclusion criteria and GA matching.
In another group of patients, blood was collected at the time of diagnosis of PE (N=20,
mean GA=33.6 weeks, SD=3.71) and non-PE (N=20 mean GA= 34.1 weeks, SD=4.2) patients of
similar GA.
Enzyme-Linked Immunosorbent Assay (ELISA)
Patient blood plasma was separated by centrifugation at 1000 RPM for 10 minutes.
ELISAs for HBEGF, EGF, and TGFA were performed using DuoSet ELISA kits (R&D Systems,
Minneapolis, MN), as previously described [30]. Standard curves were constructed for each
assay and optical density of the final reaction products were determined at 450 nm using a
programmable PowerWave (BioTek Instruments, Winooski, VT) microplate spectrophotometer
with automatic wavelength correction.
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Immunocytochemistry (ICC) and quantification by image analysis
Formalin-fixed, paraffin-embedded tissue sections were labeled by ICC, as previously
described [26, 86]. Briefly, staining procedures were performed using a DAKO autostainer
universal staining system (Carpintera, CA).

Slides were labeled with an antibody against

p110/EGFR [87] or affinity purified polyclonal antibodies raised against the recombinant
proteins, HBEGF, EGF, TGFA, BTC, AREG, and EREG (R&D Systems).

Each primary

antibody was titered using HTR-8/SVneo human cytotrophoblast cells grown on slides to ensure
that labeling was linear with antibody concentration, as previously shown [86].

Primary

antibody controls were performed using non-immune IgG (Jackson Immunoresearch
Laboratories, West Grove, PA). To assess the abundance of trophoblast cells in the tissues
studied, adjacent sections were labeled with cytokeratin-7 (KRT7) using a monoclonal antibody
(DAKO).

Bound primary antibody was visualized using a peroxidase-conjugated polymer

coupled to anti-rabbit and anti-mouse-IgG (EnVision Systems Peroxidase, DAKO). Slides were
viewed under a DM IRB (Leica, Wetzlar, Germany) inverted microscope and brightfield images
were obtained using an Orca (Hamamatsu, Hamamatsu City, Japan) digital camera or a Spot Jr.
(Diagnostic Instruments, Inc., Sterling Heights, MI) color digital camera. Stain intensity was
determined using simple PCI (Hamamatsu) image analysis software from monochrome images
of three regions of each specimen, as detailed and validated elsewhere [86]. Average pixel
densities are reported as grey level. Background grey level (non-immune IgG) was subtracted
from each image to obtain the grey level values reported. Semi-quantification of p110/EGFR
labeling was conducted using H scores. Three blinded observers assigned an H score [88] by
subjectively scoring the staining intensity as 0, 1, 2, or 3. The three H scores were averaged for
each image.
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Cell culture and treatment
HTR-8/SVneo cytotrophoblast cells [89, 90] were grown in 96 well plates and cultured in
DMEM/F12 medium containing 10% fetal bovine serum. Prior to experimentation, medium was
replaced with serum-free media containing 5 mg/ml bovine serum albumin. Control cells were
cultured at 2% oxygen for 8 hours in survival studies. H/R was modeled by culturing cells at 2%
O2 for 2 hours, followed by culture at 20% O2 for 6 hours [19]. Cells were treated during the
reoxygenation period by supplementing with medium pre-equilibrated at 20% with 0 nM, or
1nM of EGF, TGFA, AREG, HBEGF, BTC, or EREG. Intravenous administration of MgSO4 to
patients with severe PE is the standard of care for seizure prophylaxis. Therefore, to determine
the effect of MgSO4 on HBEGF expression, cytotrophoblast cells cultured at 20% O2 were
treated with 0, 2, 5, and 10 mM MgSO4 for 24 hours, 72 hours, or 7 days. Concentrations of
0.75-1.2 mM/liter of MgSO4 are equivalent to 1.5-2.4 mEq/liter blood concentration.

The

concentrations chosen in our experiment cover the therapeutic blood level concentrations of 3.57 mEq/liter we would anticipate to see in PE patients treated with MgSO4 [91]. Cells were fixed
with 4% paraformaldehyde at the conclusion of all in vitro experiments before subsequent
analysis.
TUNEL assay for cell death
Cell death was detected by terminal deoxunucleotidal transferase-mediated deoxyuridine
5-triphosphate nick and labeling (TUNEL), using a fluorescein-based kit from Roche Applied
Science (Indianapolis, IN).

Cells were counterstained with 5 ug/ml of 4',6-diamidino-2-

phenylindole (DAPI). Fluorescent images were acquired with a Leica DM IRB epifluorescence
microscope and an Orca digital camera. The TUNEL index was determined by calculating the
percentage of TUNEL positive to DAPI labeled cells in triplicate fields in each well, as described
previously [19, 30].
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Statistical analysis
SPSS (version 20.0) was used for statistical analysis. Stain intensities for proteins were
compared among the four patient groups using Kruskal-Wallis analysis due to a non-normal
distribution of the data. p110/EGFR staining intensities, blood levels, and demographic data
were compared among the four patient groups using Steel-Dwass method due to non-normal
distribution. One-way ANOVA was used to determine effects of MgSO4 on HBEGF staining
and H/R injury on TUNEL index. Spearman’s rho was used to compare protein levels in the
basal plate and chorionic villi to GA for PTL, PE, and SGA groups.
Results
EGF-like growth factors in human placentas
It was previously reported that HBEGF is expressed in KRT7-positive villous and
extravillous trophoblast cells [26]. Preliminary studies demonstrated no reactivity to antibodies
against neuregulin/heregulin in human placental tissues above control labeling with non-immune
IgG (data not shown); however, other members of the EGF family were expressed. The cellular
distributions of EGF, TGFA, HBEGF, AREG, EREG and BTC were similar in the placentas of
women delivering preterm or at term (data not shown), and each antigen was detected above the
non-immune IgG controls (Figure 1). However, there were relatively high levels of each growth
factor in the villous trophoblast layer and in extravillous trophoblast cells invading the basal
plate (arrows in Figure 2).
Although HBEGF expression appeared to be strongest in trophoblast cells, staining in
excess of the non-immune IgG control levels was present throughout the placental tissue (Figure
2).

To gain insight into which cells produce HBEGF, tissue sections were treated with

heparitinase prior to ICC to eliminate peripherally bound, secreted HBEGF. After heparitinase
treatment, HBEGF was predominantly found in cytotrophoblast cells of the chorionic villi and in
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putative extravillous trophoblast cells at the basal plate (Figure 2), suggesting the cellular source
of this growth factor.

Figure 2: Localization of EGF family proteins in normotensive placentas. Paraffinembedded sections of human placental tissues were labeled by immunohistochemistry with
primary antibodies against KRT7 (A), EGF (B), TGFA (C), HBEGF (D), BTC (F), AREG (G),
EREG (H), and non-immune IgG (E). Arrows indicate putative extravillous trophoblast cells in
the basal plate regions, based on KRT7 labeling patterns in adjacent sections. I–N.
Immunohistochemistry for HBEGF before (I, L) and after (J, K, M, N) sections were treated with
heparitinase to eliminate peripherally bound, secreted HBEGF. The latter sections reveal the
cellular origin of HBEGF in the basal plate (J, K) and chorionic villi (M, N). Higher
magnification images of basal plate and chorionic villi are shown in panels K and N,
respectively. Scale bars indicating 50 μm are shown in panels E, M and N. The size bar in panel
E corresponds to A through H. The size bar in panel M corresponds to panels I, J, L, and M,
whereas the size bar in panel N corresponds to N and K.
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EGF-like growth factors and p110/EGFR in normal and pathological placentas
Six EGF family growth factors were assessed in placentas from normotensive (N=41) and
hypertensive (N=35) women delivering between 23 and 40 weeks of gestation. The patients
were further subdivided into four groups: 1) normotensive women delivering at term (N=7); 2)
patients with PE (N=35); 3) patients of similar GA at delivery with women with PTL (N=17);
and 4) women delivering SGA infants (N=17). No differences in growth factor levels were
found between placentas of multiparous (19) and nulliparous (16) women with PE (not shown),
so all data for PE women were combined in the analysis of semi-quantitative data.
Table 1. Patient demographic data in all four cohorts

Measurable parameters for each studied group were compared to PE using a non-parametric pair-wise
comparison. Medians are reported with inter-quartile ranges (IQR). Those with significant difference (compared
to PE) are bolded and indicated with an asterisk. (p < 0.05, N/R = Not Reported).

Demographic patient data are represented in Table 1. Median GA levels were similar in
the PE, SGA, and PTL, and were 32.6, 32.9, 32.9, respectively. Significant differences were
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found in the highest systolic and diastolic blood pressure values and proteinuria levels between
the PE group compared to SGA, PTL, and term groups.
Median staining intensity values of each growth factor in the basal plate or chorionic villi
are presented in Figure 3. HBEGF was significantly reduced in both the chorionic villi and basal
plate of placentas from pregnancies with PE, compared to term, PTL, and SGA groups. Median
TGFA staining demonstrated a similar statistically significant down-regulation in the basal plate
and chorionic villi of placentas from women with PE compared to all other groups. The other
statistically significant difference in TGFA was found in the chorionic villi between term
placentas and those of SGA fetuses. Expression of EGF in the basal plate of placentas from
patients with PE was significantly reduced compared to all other patient groups. Higher EGF
staining was detected in the chorionic villi of term placentas, differing significantly from SGA
and PE placentas, but not from PTL. There were no significant correlations between GA and
expression of HBEGF and TGFA in the basal plate and chorionic villi in any groups. For EGF,
there was a significant increase seen with GA in the basal plate (P=0.029) and chorionic villi
(P=0.006) of the PE group only (Figure 4).
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Figure 3: Quantification of growth factor levels in placental tissues. Immunohistochemical
labeling of the indicated growth factors was quantified by image analysis of the basal plate (BP)
or chorionic villous (Villi) regions of placental sections from pregnancies with preterm labor
(PTL), small for gestational age infants (SGA), preeclampsia (PE) or term delivery (TERM). The
y-axis is the grey level in arbitrary units after subtracting the value for non-immune IgG controls.
The thick horizontal line indicates a value of 0. * p < 0.05 compared to all other groups. In other
panels, a,b,c, groups with the same lower case letters are not different, whereas groups with no
letters in common, p < 0.05.
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Figure 4: HBEGF, EGF and TGFA Expression with GA in Placental Tissues.
Immunohistochemical labeling of the indicated growth factors was quantified, as in Figure 2, in
the basal plate or chorionic villi. The grey level in arbitrary units is shown for individual patients
at the GA when they delivered at term (purple), preterm (PTL, blue), with a small for GA infant
(SGA, green) or with preeclampsia (PE, yellow). The thick horizontal line indicates a value of 0.
The reduced expression of these growth factors in PE placentas could be the result of a
decrease in the trophoblast cells due to apoptosis or failed invasion of the basal plate. However,
the

distribution

of

trophoblast

populations

within

the

placenta

demonstrated

by

immunocytochemical labeling of KRT7 (Figure 2) was not quantitatively different (ANOVA;
p=0.08 in villi; p=0.10 in basal plate) among the PTL, SGA and PE groups in the basal plate or
chorionic villi (Table 2). Due to the fact that most patients with PE are treated with MgSO4 for
seizure prophylaxis, it is important to understand whether HBEGF expression is altered by
MgSO4 in trophoblast cells. Culturing HTR-8/SVneo human cytotrophoblast cells with MgSO4
at doses of 2 to 10 mM for 1 to 7 days did not significantly alter HBEGF expression (Table 3).
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Table 2. KRT7 levels in the basal plate and chorionic villi amongst all cohorts of patients
Group

Cytokeratin in Basal Plate
(Grey Level)

PTL

19.5 ± 10.2

Cytokeratin in Chorionic
Villi
(Grey Level)
25.4 ± 6.7

SGA

15.9 ± 9.1

19.5 ± 9.0

PE

12.7 ± 8.3

20.1 ± 8.3

P

0.10

0.08

Data are mean ± SEM. Cytokeratin 7 levels determined by quantitative immunohistochemistry were compared by
ANOVA among patient groups separately for the basal plate and chorionic villous placental regions.

Table 3. HBEGF expression in HTR-8/SVneo cells cultured with varying doses of MgSO4
HBEGF (Grey Level)

[MgSO4]
(mM)

24 hours

72 hours

7 days

0

9.68 ± 1.45

10.03 ± 3.78

7.68 ± 0.02

2

10.43 ± 1.06

9.99 ± 0.98

9.89 ± 2.77

5

8.79 ± 12.08

10.59 ± 3.41

8.75 ± 0.58

10

8.43 ± 5.61

9.53 ± 4.73

8.54 ± 2.80

P

0.73

0.91

0.26

Data are mean ± SEM. HTR-8/SVneo cytotrophoblast cells were cultured up to 7 days in medium containing the
indicated concentrations of MgSO4, then fixed and labeled with anti-HBEGF for quantitative
immunohistochemistry. HBEGF levels were compared by ANOVA at each time point for significant differences
among MgSO4 concentrations.

In contrast to EGF, TGFA and HBEGF, the median staining intensities of BTC, AREG
and EREG were not consistently down-regulated in placentas from women with PE, as compared
to the other patient groups (Figure 3). BTC was significantly elevated in the chorionic villi at
term compared to all other groups and in the basal plate compared to SGA and PE. In chorionic
villi, AREG was significantly elevated in term placentas compared to preterm labor and
preeclampsia, and in the basal plate compared to preterm labor. EREG demonstrated a
significant increase with SGA as compared to PE and PTL in chorionic villi and as compared to
PE in the basal plate.
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The EGFR splice variant p110/EGFR was strongly expressed on the surface of chorionic
villi of placentas at term, but not placentas delivered preterm (Figure 5). In placentas from
patients with PE that were not at term, p110/EGFR was also highly expressed. However,
antibody against full-length ERBB1/EGFR strongly labeled placentas of both the preterm labor
and PE groups (Figure 5), a result that was distinct from p110/EGFR. Because P110/EGFR was
confined to the periphery of the villi, it was not compatible with the image analysis method used
for EGF family growth factors. Therefore, staining of P110/EGFR was semi-quantitative by H
score, which confirmed significant elevation in PE, as compared to SGA and PTL patients;
however, P110/EGFR levels in term placentas were comparable to PE patients (Table 4).

Figure 5: Expression of p110/EGFR and full-length ERBB1/EGFR in Placental Tissues.
Immunohistochemical labeling of p110/EGFR in placental section from patients delivering
preterm (A), at term (B) or with preeclampsia (C). For comparison, ERBB1/EGFR labeling in
placentas of patients delivering preterm (D) and with preeclampsia (E) are shown.
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Table 4. H scores for p110/EGFR in PTL, SGA, term, and PE
Groups
PTL
SGA
Term
PE

Median (IQR)
0 (0–0)
0 (0–0.33)
1.83 (1.25–3)
2.67 (0.33–3)

Significance
a
a
b
b

H scores were determined by the average of three blinded observers' subjective readings between 0 and 3 for PE
(N = 29), PTL (N = 10), SGA (N = 13), and term (N = 6) to each labeled placental section to indicate the level of
p110/EGFR immunohistochemical staining. Labeling was predominantly on the surface of the chorionic villi. The
readings were averaged and analyzed using non-parametric statistics. Medians and inter-quartile ranges (IQR) are
shown.

EGF-like growth factors are cytoprotective for trophoblast
Previously, we found that apoptosis is low and not significantly different when human
first trimester trophoblast cells are cultured at either 20% or 2% O2, but increases significantly
after switching from low to high O2 [19].

In an H/R model using the HTR-8/SVneo

cytotrophoblast cell line, cell death due to H/R injury was blocked by supplementation with the
EGF-like growth factors, HBEGF, EGF, TGFA, EREG or BTC (Figure 6). Cell death was not
significantly reduced by AREG, although there was a downward trend.
Figure 6: Prevention of apoptosis due to H/R by EGF-like growth factors. Experiment was
run in triplicate. HTR8/SVneo cytotrophoblast
cells
were
cultured at 2% O2
(Hypoxia) or exposed
to 2% O2 for 2h
followed by 6h at 20%
O2 (H/R). In other
treatments,
culture
medium
was
supplemented
with
1nM of the indicated
growth factors during
H/R. Apoptosis was
assessed by TUNEL
assay.
*p<0.05
compared to hypoxia.
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Plasma EGF levels
Circulating EGF, TGFA and HBEGF were examined preterm in a separate group of
women who either were diagnosed with PE or were normotensive and later delivered at term.
The average age of the patients in the normotensive (26 ± 4.6) and PE (24 ± 7.7) groups and the
GA at time of blood draw in the normotensive (33.6 ± 3.7) and PE (34.1 ± 4.1) groups were not
significantly different. The median blood plasma concentrations of HBEGF and TGFA in PE
patients were not significantly different from normotensive control patients (Figure 7).

Figure 7: Serum growth factor concentrations in non-preeclamptic and preeclamptic
patients. Box plot represents comparisons of EGF, HBEGF, and TGFA blood levels. Values are
represented as median with inter-quartile range. *denotes outlying values. Significant decrease (p
< 0.05) was found for EGF levels in the PE group compared to the non-PE group.
However, median control plasma EGF levels (324.3 pg/ml) were more than double
(p<0.05) the median concentration (147.5 pg/ml) in PE patients (Figure 7). Regression analysis
indicated no effect of GA on EGF plasma levels in either the control (R2=0.0040) or PE
(R2=0.0055) group.
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Discussion
We report, for the first time, evidence for broad down-regulation of the EGF signaling
system in trophoblast cells of placentas from PE pregnancies. In agreement with our previous
report [26], it was demonstrated that HBEGF protein levels are significantly decreased in PE
placentas as compared to term, PTL, and SGA placentas. HBEGF dysregulation could play a
critical role in the etiology of PE, particularly if other components of the EGF signaling system
contribute to suppression of signaling. Indeed, TGFA and EGF were also significantly lower in
placentas from women with PE, further supporting the hypothesis that deficiencies of the EGF
signaling system in PE contribute to improper extravillous trophoblast differentiation and
increased apoptosis. Since EGF, TGFA and HBEGF are each capable of altering integrin
expression associated with increased motility and invasiveness of human trophoblast cells [29],
their deficiency could contribute to uteroplacental insufficiency. Others have shown that TGFA
promotes cytotrophoblast proliferation [92] and that EGF promotes trophoblast invasion [84].
Furthermore, the EGF signaling system can limit trophoblast apoptosis, as demonstrated during
H/R injury of cultured cytotrophoblast cells and here elsewhere [19, 30, 81, 82, 93-95]. The
reason for dysregulation of EGF family growth factors in PE is not clear; however, a genetic
predisposition is suggested by polymorphisms in the HBEGF gene associated with the
development of PE [96]. There were no differences found in expression of EREG between PE
and term or PTL.

Although AREG and BTC were significantly altered in PE placentas

compared to term, they were comparable to GA-matched PTL and SGA patients of similar GA,
suggesting a GA effect.
Although some EGF-like growth factors are expressed normally in PE, it is not known
whether their activity is sufficient for trophoblast survival and invasion in vivo. BTC and EREG
were as effective as HBEGF, EGF and TGFA in blocking H/R induction of apoptosis in cultured
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cytotrophoblast cells. However, the function of residual EGF-like growth factor expression in
PE could be suppressed by truncated ERBB splice variants that act as antagonists or dominant
negative. One such protein shown here to be highly expressed in placentas of PE women is
p110/EGFR,

a

110-kDa

isoform

of

the

EGF

receptor

thought

to

contain

a

glycosylphosphatidylinositol anchor [97]. Indeed, p110/EGFR was previously isolated from
human placentas [97]. There are other truncated isoforms of the EGFR produced by alternate
mRNA splicing or proteolytic cleavage of the full-length receptor [98]. Evaluation of EGFR
mRNA expression in PE placentas revealed significantly higher levels of the truncated transcript
[85]. Consistent with those findings, we found an increase in p110/EGFR in placentas of PE
patients, compared to SGA and PTL patients. Given that p110/EGFR contains an extracellular
domain and lacks an intracellular cytoplasmic domain, it should provide no intracellular
signaling upon EGF binding and act as a dominant negative. The high levels of p110/EGFR
found in PE placentas could, therefore, exacerbate the paucity of EGF family growth factors.
p110/EGFR also increased in term placentas, confirming a previous report that EGFR rises
significantly at term [99]. The increase in P110/EGFR at term suggests a need to downregulate
the EGF signaling system at term, as persistent trophoblast invasion is noted in patients with
post-partum hemorrhaging due to subinvolution of the utero-placental arteries [100]. Further
studies are required to evaluate the precise function and clinical relevance of this EGF receptor
isoform as it pertains to PE and parturition.
Patients with severe PE, similar to the PE cohort studied here, are routinely treated with
MgSO4 for seizure prophylaxis, as is the standard of care. To ensure that the decrease in
HBEGF found in PE placentas was not an effect of MgSO4 administration, cytotrophoblast cells
were cultured in MgSO4 for up to 7 days. No significant dose-dependent decrease in HBEGF
was found after MgSO4 treatment in vitro, suggesting that MgSO4 is not responsible for the low
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levels of HBEGF in PE placentas. Furthermore, the decreased expression of HBEGF, TGFA and
EGF in PE placentas could not be explained by a significant reduction of trophoblast cells
populating the chorionic villi or basal plate, based on comparable expression of the trophoblast
marker protein KRT7 in all patient groups.
It is well-established that placentas are subject to numerous forms of stress during
pregnancy, including oxidative and inflammatory stress [80, 101]. PE placentas have increased
rates of apoptosis, presumably related to oxygenation injury [74, 75]. Injury could be caused by
oxygen radicals produced by abnormally high levels of oxygen during placentation [102].
Previously, we reported that survival of human first trimester cytotrophoblast cells at the low O2
concentrations experienced by the conceptus during the first 10 weeks of pregnancy [14, 103]
correlates with a pronounced up-regulation of HBEGF [30]. Here, we show that HBEGF, EGF,
TGFA, BTC, and EREG can each prevent cell death in a cytotrophoblast cell line due to
oxidative stress caused by H/R.

We have previously found that exogenous application of

HBEGF to cytotrophoblast cultures will prevent apoptosis caused by experimentally-induced
oxidative stress and that the effect is dependent on the ERBB receptor mediated downstream
signaling [19, 30, 94]. These findings are consistent with previous studies that have shown that
EGF reduces apoptosis in trophoblast cells [104].
Because EGF, HBEGF, and TGFA are decreased in placental tissues from PE, we
examined the possibility that their blood levels are altered in PE patients. Plasma EGF levels
were significantly decreased in patients with PE compared to those without the disease, while
HBEGF and TGFA were unaffected.

The absence of a difference in TGFA between

preeclamptic and non-preeclamptic patients could reflect the very low levels of TGFA detected
in serum. HBEGF is secreted by multiple organs [105], possibly overshadowing the contribution
from the placenta. Furthermore, heparan sulfate expressed on the trophoblast surface might
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retain HBEGF produced in the placenta. The decrease in circulating EGF of PE patients is
consistent with the decreased expression by the placenta. Previous studies evaluating EGF blood
levels in IUGR, which shares similar placental pathophysiology with PE [6], have yielded
inconsistent results. Similar to our study, an evaluation of EGF plasma levels in IUGR patients
found significantly lower levels compared to non-IUGR patients [106], while another study
evaluating blood EGF levels in IUGR patients found no difference [107]. Our findings suggest
that EGF blood levels are dysregulated in patients with PE. It would be important to further
assess EGF blood levels prior to the clinical onset of PE and follow these patients to term. If
dysregulated EGF blood levels predate the placental phenotype seen at the time of diagnosis of
PE, then dysregulation of EGF could contribute to placental disease. Furthermore, EGF blood
levels might be useful as a pre-clinical biomarker.
We have presented new information reporting that several members of the EGF family
are decreased in the placentas patients with PE, suggesting a role in its etiology. This study
evaluated placentas at delivery; however, disruption of the EGF signaling system likely occurs
early in pregnancy. It is not possible to study first trimester placentas in PE patients because the
disease is not diagnosed until at least 20 weeks of gestation. The utility of this approach awaits a
non-invasive and safe method of evaluating trophoblast expression early in pregnancy.
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CHAPTER III
NON-INVASIVE DETECTION OF TROPHOBLAST PROTEIN SIGNATURES LINKED
TO EARLY PREGNANCY LOSS USING TRIC
Introduction
EPL is a common pregnancy complication with the incidence of clinical pregnancy loss
approaching 15% [37]. Including preclinical losses, the overall rate of pregnancy loss exceeds
50% [108]. Aneuploidy, one of the leading causes of EPL, accounts for approximately 50% of
occurrences; however, a large proportion still remains idiopathic [109]. Recurrent pregnancy
loss, defined as two or more pregnancy losses, occurs in approximately 2-5% of patients, and
despite an extensive workup, the cause remains unknown in up to 75% of cases [110].
Proper implantation and placentation are necessary for adequate fetal development. A
critical step in this process throughout the first and second trimesters is the penetration of EVT
cells through the decidua and inner one third of the myometrium, followed by remodeling of the
spiral arteries [7]. Remodeling of the uterine spiral arteries transforms narrow, high-resistance
blood vessels into dilated, low-resistance conduits of maternal blood into the intervillous space
[8]. Shallow EVT invasion and failure to convert the maternal spiral arteries contribute to
uteroplacental insufficiency that can result in pregnancy complications, including IUGR and PE
[9, 10]. Prior to 10 weeks of gestation, maternal blood flow to the intervillous space is limited
due to formation of an endovascular plug by EVT cells within the spiral arteries, reducing
turbulence at the anchoring villi and lowering oxygen tension [12]. It has been suggested that
this environment ensures proper growth and protects the early developing placenta from
oxidative and mechanical stress [6, 12, 13]. Premature blood flow to the intervillous space due
to inadequate EVT plug formation has been linked to EPL [12], and polymorphisms in genes
related to antioxidant production are found in women with recurrent idiopathic miscarriages
[111]. Indeed, EPL specimens have revealed a strong incidence of deficient EVT proliferation
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and invasion, suggesting a central role for EVT cells in this pathology [40].
Information about first trimester EVT cells in the context of pregnancies with adverse
outcomes is important in light of molecular studies of EVT cells at the time of delivery.
Signaling systems that regulate EVT differentiation and survival [27, 82, 84], are disrupted in
diseases related to uteroplacental insufficiency [26, 112]. Whether these signaling systems are
dysregulated during placentation or simply disrupted due to events arising late in the disease
process can only be addressed by accessing EVT cells in the first trimester without disrupting
pregnancy outcome. Obtaining intact trophoblast cells from ongoing pregnancies has been
limited to CVS, which is almost exclusively preformed for prenatal genetic diagnostics.
Moreover, CVS is invasive, and is associated with a pregnancy loss rate of approximately 0.5%1.0% [44]. Therefore, acquisition of trophoblast cells by CVS to investigate their dysfunction in
EPL is not feasible.
Trophoblast cells are shed into the lower uterine segment during pregnancy, and can be
retrieved by minimally invasive methods from the cervix of ongoing pregnancies as early as 5
weeks of gestation [49]. Historically, the limiting step in employing these cells for placental
evaluation was the inability to isolate them free of maternal cervical cells [49]. Recently, TRIC
has enabled isolation of EVT cells after a Papanicolaou procedure with 90-100% purity in a
minimally invasive approach [68].

EVT cells are separated from maternal cells, using

immunomagnetic isolation with antibody against HLA-G, an EVT-specific protein. The isolated
cells have the expected EVT protein expression pattern [68].
We hypothesized that EVT cells obtained by TRIC from EPL patients have specific
protein expression signatures compared to healthy control pregnancies. To test this hypothesis,
we obtained EVT cells by TRIC and evaluated seven proteins altered in pregnancy disorders
related to placental dysfunction. Galectin 13 (LGALS13), galectin 14 (LGALS14), pregnancy-
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associated plasma protein-A (PAPPA), and placental growth factor (PGF) are proteins secreted
by the placenta that decrease in both placentas and serum of women with adverse pregnancy
outcomes associated with abnormal placentation, such as preeclampsia [113-117]. Elevated
levels of endoglin (ENG), fms-like tyrosine kinase-1 (FLT1), and alpha-fetoprotein (AFP), have
been found in placentas or serum of patients with adverse pregnancy outcomes related to
abnormal placentation [118-122]. EPL is theorized to share a similar pathophysiology with
preeclampsia, stemming from abnormal placentation [6]. Therefore, expression of these seven
proteins was evaluated in EVT cells obtained by TRIC in specimens from EPL and healthy
controls delivering at term.
Materials and Methods
Patient selection
The Institutional Review Board of Wayne State University approved this study and each
participating patient was provided with informed consent. Patients were counseled for collection
of endocervical samples at Wayne State University or affiliated clinics. Exclusion criteria
included viable pregnancies with a history of vaginal bleeding. All the patients included in this
study had singleton gestations. Medical records were evaluated to identify pregnancies with a
diagnosis of an EPL (N=10), and control pregnancies, matched for GA, were selected that
resulted in healthy term deliveries (N=10). GA was determined by the date of the last menstrual
period and the first ultrasound. Eight of 10 case specimens were collected at or after diagnosis of
EPL, while 2 specimens were collected prior to awareness of an EPL (Table 5).
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Table 5. Characteristics of EPL patients
EPL Patient

GA at time of
ECS

EPL known at
time of ECS

A

5w6d

Yes

B

8w

Yes

C

6w5d

Yes

D

7w4d

Yes

E

7w2d

Yes

F

7w5d

Yes

G

7w5d

Yes

H

8w

Yes

I

5w

J

7w3d

USG findings
(relation to ECS)
+ FP, ‐FH
(‐1d)
Empty GS
(‐1d)
Empty GS
(‐1d)
Empty GS
(‐7d)
+ FP, ‐ FH
(‐1d)

β‐hCG
(relation to ECS)
7,925
(‐1d)
66,290
(‐1d)
27,970
(‐1d)
20,383
(‐7d)
N/A

Empty GS
(‐2d)
+ FP, ‐FH
(‐1d)

16
(0), 2,166
(‐10d)
44,753
(‐2d)
17,024
(‐4d)

No

+FP, ‐FH (+7d)

4,972 (+7d)

No

+ FP, ‐FH (+14d)

16,775 (+14d)

Empty GS
(‐7d)

Ten patients with EPL. Parenthesis represent relation of ultrasound and β-hCG to time of ECS, with minus (–)
representing prior to ECS and positive (+) representing time after ECS Abbreviations: ECS- Endocervical sample,
FP- fetal pole, FH- fetal heart tone, GS- gestational sac, w- weeks, d- days.

Endocervical sampling
Endocervical sampling was performed, as described previously [58]. Briefly, a vaginal
speculum was used, and endocervical specimens were collected using a cytobrush and a
ThinPrep kit (Hologic, Inc., Marlborough, MA) containing 20 ml of PreservCyt fixative solution.
The specimens were transferred to the laboratory, where they were acidified with 500 μl of
glacial acetic acid for 5 minutes to dissolve the mucous. Samples were centrifuged at 400 × g for
5 minutes at 4°C. The supernatant was removed and the cell pellet was re-suspended in 20 ml of
ice-cold sterile phosphate buffered saline (PBS). Specimens were then washed by centrifugation
and re-suspension three times with 2.0 mL of PBS, and on the final wash, the specimen was
brought to 10 mL with PBS at 4°C.
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Isolation of EVT cells
The endocervical specimens were centrifuged and re-suspended in 1.5 ml of PBS,
combined with mouse anti-HLA-G antibody conjugated to 250 nm magnetic nanoparticles
(Clemente Associates, Madison, CT), and incubated overnight at 4°C with mixing. The EVT
cells bound to magnetic nanoparticles were then immobilized on a DynaMag-Spin magnet (Life
Technologies) for 10 minutes.

The non-bound cells were collected, followed with three

washings in 1 ml of PBS. The bound cells were divided into aliquots of approximately 20-50
cells in 200 μl of PBS, and spun onto microscope slides using a Shandon Cytospin 3 centrifuge
(Thermo-Fisher, Waltham, MA) at 1500 RPM for 5 minutes. The isolated cells were checked for
purity by ICC labeling of the trophoblast marker, human chorionic gonadotropin β-subunit (βhCG) and determining the percentage of cells labeled with β-hCG/DAPI, as described previously
[68].
ICC
Slides containing isolated EVT cells were incubated for 17 hours at 4°C in Tris-buffered
saline containing 0.05% Tween-20 and 5 mg/ml BSA (TTBS/BSA) with 10 μg/ml of mouse
antibody against β-hCG, or 5 μg/ml of primary antibody recognizing ENG, FLT1, AFP, PAPPA,
LGALS13, LGALS14, or PGF. Antibodies are described in Table 6. Each antibody was
initially titered to ensure a linear fluorescence signal with labeling (Figure 8) and similar
antibody lots were used throughout the study. To evaluate background fluorescence, control
slides were incubated with 5 μg/ml of non-immune rabbit, goat, or mouse IgG (Jackson
ImmunoResearch), as appropriate.

Slides were washed three times with TTBS/BSA and

incubated for 1 hour in the dark at room temperature with similar lots of FITC- or Texas Redconjugated, species-specific, secondary antibodies (Jackson ImmunoResearch) diluted 1:250 in
TTBS/BSA. Slides were washed three times with TTBS/BSA and nuclei were counterstained
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with 1 ng/ml DAPI for 10 min, followed by three washes with TTBS/BSA. Slides were cover
slipped with Vectashield mounting media (Vector Laboratories, Burlingame, CA) and sealed
with nail polish.
Table 6. Antibodies used for EVT protein expression by ICC
Antigen
β-hCG
Endoglin (ENG)
Fms-like tyrosine kinase-1 (FLT-1)
Alpha-fetoprotein (AFP)
Pregnancy-associated plasma
protein-A (PAPP-A)
Galectin-13 (LGALS13)
Galectin-14 (LGALS14)
Placental growth factor (PGF)

Clone
5H4-E2
2022
2321
189506

Species
Mouse
Goat
Goat
Mouse

Company
Pierce Biotechnology
R&D Systems
R&D Systems
R&D Systems

5069

Goat

R&D Systems

EPR2898(2)
511124
358905

Rabbit
Mouse
Rat

Ambion
R&D Systems
R&D Systems

Figure 8: Antibody titration. Titration was implemented by serial dilution of antibodies in
order to calculate the optimal concentration, and to ensure the linearity of fluorescence signals.
5μg/ml was determined as the optimal concentration of all antibodies.
Protein marker quantification by image analysis
Fluorescent antibody labeling was imaged using a Hamamatsu Orca cooled-chip digital
camera and a Leica DM IRB microscope with filter sets for DAPI, FITC and Texas Red. Cells in
each field were imaged at a objective magnification of 20 × and an exposure time of 2.0 seconds.
The FITC or Texas Red stain intensities were quantified using Simple PCI (Hamamatsu)
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imaging software. Fluorescence intensities (grey levels) were determined for each antibody and
non-immune IgG (background) by circumscribing at least 10 cells. The background values were
averaged and subtracted from each fluorescent value. The background-subtracted values for
each specimen were averaged to calculate the average fluorescent units (AFU). Each AFU value
was divided by the average of the AFUs for the control cohort to generate the relative fluorescent
unit (RFU) values.
Statistical analysis and data modeling
All statistical analyses were performed using JMP (version 10.0; SAS Institute, Cary,
NC). Data were initially examined for normality using the Shapiro-Wilk test and between-group
differences in RFU for each protein biomarker were analyzed with the non-parametric Wilcoxon
rank-sum test, as the data were not normally distributed. Spearman’s rho was used to assess for
correlation between GA and trophoblast yield. A value of p < 0.05 was considered statistically
significant.
Principal component analysis (PCA) was implemented to assess the ability of the
biomarker panel to separate individual data points (score plot) by projection of the original data
on the first two principal components (PC1 and PC2), as well as correlations among biomarkers
(loading plot). This useful statistical tool reduces the complexity of multidimensional data
models by linearly combining multiple factors and downsizing them into new variables or
principal components, while retaining the original information [123].
Results
Isolation of EVT cells
The GA of pregnancies at the time that TRIC specimens were obtained ranged between 5
and 8 weeks in the EPL cohort, and between 6 and 10 weeks in the control cohort, with similar
median GAs of 7.5 and 7.8 weeks, respectively (Table 7). The median maternal age in the EPL
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and control cohort were not significantly different, at 29.5 and 25.0, respectively. However, the
median number of EVT cells recovered by TRIC in the EPL group was approximately 25%
(p<0.05) of that recovered in the control group (Table 7). Immunofluorescence labeling of βhCG revealed a comparable median EVT purity of 96.9% in EPL specimens and 99.1% in the
control group (Table 7, Figure 9).

There was no significant correlation between GA and

trophoblast yield in the group of 20 patients that provided endocervical specimens between 5-10
weeks GA.
Table 7. Patient and specimen characteristics

The differences in parameters related to recovered fetal cells (Count, Purity) were compared using
the non-parametric Wilcoxon test. The significant differences (p<0.05) are bolded and labeled
with an asterisk. N/R, not reported; IQR, interquartile range.
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Figure 9: Expression of β-hCG in cells isolated by TRIC. Cells were labeled with anti- β-hCG
were examined by immunofluorescence microscopy. Image of β-hCG secondary antibody
conjugated with to FITC (green) appear in panel A, with matching fields of nuclei counterstained
with DAPI (blue) in panel B. Overlay with FITC and DAPI appear in panel C.(scale bar = 100
μm)
Protein expression in isolated EVT cells
In the EPL cohort, compared to the controls, expression levels for AFP, FLT1 and ENG
were elevated (p< 0.05), while PGF, LGALS14, and PAPPA were significantly (p< 0.05)
reduced (Figures 10 & 11). LGALS13 labeling revealed equivalent expression in the EPL and
control cohorts.
Figure 10: Quantification of biomarker expression in TRIC-isolated EVT cells. EVT cells
labeled with antibodies against the indicated proteins were imaged to obtain the relative
fluorescence unit (RFU) values, as described in the Materials and Methods. The non-parametric
Wilcoxon
test
was
employed to compare the
expression of each protein
marker between control
(white)
and
early
pregnancy loss (EPL)
(black)
groups.
The
significant
differences
(p<0.05) are indicated by
a bar and asterisk above
the control/EPL pairs. Box
= 25th to 75th percentiles,
horizontal line within the
box = median, whisker =
1.5 × Inter Quartile
Range (3rd quartile – 1st
quartile).
The
dots
represent
individual
outliers.
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Figure 11: TRIC-isolated EVT cells imaged for biomarker expression by
immunocytochemistry. Shown are examples of EVT cells labeled with antibodies against PGF,
PAPPA and LGALS14 in A, and ALF, FLT1 and ENG in B. The first column of images depicts
DAPI-labeled nuclei for the control group. The second column depicts the corresponding protein
expression for the control group. The third column depicts protein expression for the EPL group,
and the fourth column depicts the corresponding DAPI staining for the EPL group. (scale bars =
100 μm)
Principal component analysis (PCA)
PCA was employed to examine whether the two cohorts could be distinguished with the
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protein expression panel.

The PCA score plot was generated over the first two principle

components, accounting for 75.8% of the total variance, which separated the EPL and control
specimens (Figure 12A). The loading plot revealed two distinct groups of biomarkers (AFP,
FLT1, and ENG; and LGALS14, PAPPA, and PGF; Figure 12B).
B)

A)

PC 1 (40.9%)

PC 1 (40.9%)

Figure 12: Principal component analysis (PCA) plots. (A) PCA scores were calculated and
plotted for individual patients over the first two principal components (PC1 and PC2). The PCA
score plot demonstrates a separation of EPL (closed circles) and control cases (open circles). (B)
The loading plot was generated for individual biomarkers to determine their relationships over
PC1 and PC2. Two groups of factors composed of associated members (AFP, FLT1, and ENG;
and LGALS14, PAPPA, and PGF) were identified by their positions along the x-axis. Note that
LGALS13 did not cluster with the other proteins.
Discussion
We evaluated EVT cell protein expression patterns from ongoing pregnancies in “real
time” by a minimally invasive method, using TRIC. This pilot study reveals that EVT protein
expression patterns are dysregulated in EPL pregnancies, compared to normal healthy controls.
These findings support the hypothesis that dysregulated EVT function is associated with EPL,
and more generally to uteroplacental insufficiency.
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In agreement with our previous study [68], we are able isolate EVT cells from the cervix
of ongoing pregnancies with a high degree of purity, based on β-hCG immunostaining.
Interestingly, significantly fewer trophoblast cells were isolated from pregnancies with EPL than
from the control group. This is consistent with our prior report that reduced numbers of EVT
cells can be detected in cervical smears from pregnant patients with ectopic pregnancies or a
blighted ovum EPL [58]. Although patients in this study were within a narrow GA range of 5-10
weeks at the time of sampling, there was no correlation with trophoblast yield. Previously, in a
larger cohort of 56 patients between 5 and 20 weeks GA, we found no correlation between GA
and trophoblast yield [68].
By evaluating expression patterns of proteins known to play a role in EVT function and
pathology, we provide evidence of EVT dysfunction in EPL. Our findings revealed decreased
expression of PGF, PAPPA and LGALS14. PGF has a similar amino acid sequence to VEGF
[124], with an important role in placental vasculogenesis and angiogenesis. It is decreased in
maternal serum from pregnancies with complications related to abnormal EVT invasion,
including preeclampsia and IUGR [116, 117]. PAPPA is produced by the placenta and can be
measured in maternal serum as early as five weeks of gestation [125, 126]. It is decreased in
maternal circulation in pregnancies with adverse outcomes, including preeclampsia, IUGR,
preterm labor, and stillbirth [115]. Low levels of PAPPA, a protease targeting insulin-like
growth factor binding protein-4 [127], permit accumulation of its circulating substrate, thereby
decreasing the bioavailability of IGF, which negatively impacts trophoblast growth and
extravillous differentiation [128]. Altered maternal immunity is critical for EVT invasion, and
the galectins LGALS13 and LGALS14 are known to have an immunoregulatory role [129-132].
Furthermore, both are decreased in placentas with severe early onset preeclampsia [114], a
syndrome that, like EPL, is associated with early EVT dysfunction [6]. While LGALS14 is
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significantly reduced in EVT cells from pregnancies that suffer EPL, no such change was
observed for LGALS13, suggesting there could be subtle differences in the molecular
mechanism of EPL and preeclampsia.
Levels of FLT1, AFP and ENG were significantly elevated in the EPL cohort. Soluble
forms of FLT1 antagonize VEGF, and are significantly elevated in serum of preeclamptic
patients [119]. FLT1 mRNA and protein expression increase in placentas from preeclamptic
patients, compared to controls [120]. The precise function of AFP is not known; however, it is
produced by the placenta, and recent evidence has linked AFP to anti-oxidant activity [133]. The
increased expression of AFP could represent a compensatory response to precocious oxygen
radical formation. ENG is a co-receptor of transforming growth factor-β that functions in
angiogenesis [134], and is expressed by trophoblast cells as early as 6 weeks of gestation [135].
ENG increases in placentas with IUGR [136], and first trimester CVS revealed increased levels
of ENG mRNA in patients destined to develop preeclampsia [118].

Furthermore, ENG

expression negatively regulates EVT differentiation and invasiveness in vitro, based on a human
chorionic villous explant model [137].
For classification and visualization of protein relationships in the control and EPL
cohorts, a two dimensional PCA score plot was generated using two principal components (PC1
and PC2). This model demonstrated that the individual components of the two cohorts have a
strong tendency to dissociate. The loading plot showed that there were appreciable correlations
among the proteins measured. A positive correlation was detected among AFP, FLT1 and ENG,
and another among LGALS14, PAPPA and PGF in the opposite direction. The ability of the
current model to distinguish the two groups of proteins is consistent with their levels in the
circulation. The panel of six responsive biomarkers could prove useful for risk assessment and
early diagnosis of EPL.
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A limitation of this pilot study is the lack of cytogenetic information to distinguish EPL
pregnancies associated with chromosomal anomalies. Cohort sizes were not adequate to identify
subgroups within the EPL or control groups. Interestingly, the early onset of intervillous blood
flow is similar in EPL with and without aneuploidy [138], suggesting a convergent etiology. It
would also have been useful to obtain the time of last vaginal intercourse before endocervical
specimen collection, as growing evidence has demonstrated a significant effect of seminal fluid
on the reproductive tract, including the cervix [139, 140]. As depicted in Table 5, eight out of
the ten EPL samples in this study were obtained after diagnosis, while two samples were
obtained prior to diagnosis. It is difficult to evaluate whether those two pregnancies were viable
at the time of sampling. In the future, it will not only be important to correlate the findings in
relation to karyotype, but also to the timing of EPL diagnosis. With a larger cohort, it might be
possible to distinguish changes in protein expression that precede pregnancy failure from those
that follow it. Obtaining an abnormal EVT protein expression pattern prior to an adverse
outcome could enable clinicians to screen for adverse outcomes related to abnormal placental
function and better evaluate therapeutic options.
The ability to obtain EVT cells from early, ongoing pregnancies and determine the
eventual outcomes provides opportunities to discover novel biomarkers through global analytic
approaches.

In addition to providing insights into the etiology of placental insufficiency,

identification of differentially expressed genes could be used for development of new biomarkers
panels, similar to the one used in the present study, to better distinguish patients at low risk of
pregnancy disorder from those at risk for specific pathologies. Early identification of at-risk
patients would greatly facilitate the evaluation of potential therapeutic interventions for
obstetrical disorders by selecting study cohorts more likely to develop disease than the general
population.
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CHAPTER IV
TRIC: NON-INVASIVE, REAL-TIME, MOLECULAR ASSESSMENT OF PLACENTAL
HEALTH IN VIVO
Introduction
Serum biomarker screening and uterine artery Doppler ultrasound are currently the
standard of care for predicting IUGR and PE before the onset of maternal disease [141].
Circulating biomarker proteins in the maternal blood, particularly those associated with
angiogenesis and the stress response, become altered several weeks before clinical symptoms of
PE or IUGR appear [142]. However, first trimester screening of multiple predictors remains
uninformative before 11 weeks of pregnancy, even when combined in a multivariable model
[143]. Thus, no reliable biomarkers are available to alert clinicians in the first trimester to
pregnancies that will eventually develop IUGR or PE, impeding progress toward targeted
management of high-risk pregnancies to lessen the impact on women and their fetuses.
Histological examination of placentas delivered by women with severe PE and IUGR
suggests a prior disruption of EVT function in the first trimester that predisposes to
uteroplacental insufficiency, characterized by reduced EVT invasion and inadequate remodeling
of the spiral arteries, with elevated EVT cell death [74-77, 144]. IUGR and PE are syndromes
that span a continuum of outcomes, ranging from mild to severe. Although it is thought that
remodeling of the uterine arteries becomes deficient before PE and IUGR are diagnosed, direct
evidence of early EVT dysfunction is lacking and the underlying cellular and molecular
mechanisms remain unknown. There is evidence that circulating proteins altered in association
with PE originate in the placental trophoblast cells, suggesting indirectly their involvement in the
disease process [141]. Conditions arising later in gestation exacerbate the onset of disease,
which can include endothelial cell dysfunction and a systemic maternal inflammatory response
that can lead to organ failure [79, 80].
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Although access to fetal cells for prenatal diagnosis is technically complex, and in some
cases poses high risk [145], a relatively simple solution to this challenge has been advanced over
the past forty years [49]. The first report identifying fetal cells from the cervix of pregnant
patients was described in 1971[146]. Following this landmark finding, multiple investigators
have isolated trophoblast cells from the cervix of pregnant patients with varying degrees of
success, ranging between 23%-97% [49]. Placental cells are shed into the cervical canal, but
their clinical utility has been limited due to an excess of co-mingling maternal cells. Successful
methods for obtaining trophoblast cells during ongoing pregnancies include antenatal cell
extractor, cervical aspiration, endocervical canal lavage, intrauterine lavage, and transcervical
smears with a cytobrush [49]. Although these methods are less invasive than conventional
methods of obtaining intact fetal cells from ongoing pregnancies, safety of the above methods
vary. Intrauterine lavage has been associated with limb reduction defects [147]. Obtaining
trophoblast cells from the cervix of ongoing pregnancies with the same cytobrush used for a
Papanicolaou test was attempted by multiple investigators [148, 149] and has been proven safe
during pregnancy [59-62].

We have taken advantage of the unique expression of human

leukocyte antigen (HLA)-G on the surface of EVT cells, exclusive of adult tissues [150],
including maternal cervical cells [58], to differentiate fetal from maternal cells. We recently
introduced TRIC to efficiently separate EVT cells in endocervical specimens from the resident
maternal cells [68]. TRIC provides approximately 1000 nearly homogeneous EVT cells for
prenatal testing, beginning at 5 weeks GA [151], before it is currently possible to determine
whether disease is developing.
We hypothesize that the molecular signatures of EVT cells early in gestation reflect their
disrupted function in at least a portion of pregnancies that later develop IUGR or PE. LGALS13,
LGALS14, PAPPA, and PGF are proteins secreted by the placenta into the maternal circulation
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that decrease in serum with abnormal placentation, prior to the onset of IURG or preeclampsia
[113-117].

Elevated levels of soluble endoglin (sENG), soluble fms-like tyrosine kinase-1

(sFLT1), and AFP, have been found in placentas or serum of patients with abnormal placentation
[118-122, 152]. These diseases share a similar trophoblast pathophysiology that derives from
abnormal placentation [6]. Therefore, expression of these seven proteins was evaluated in EVT
cells obtained by TRIC prior to 20 weeks of GA to determine whether their levels are altered in
women who later develop these disorders.
Materials and Methods
Patient selection
Endocervical specimens (N=41) were collected from women receiving initial prenatal
care after spontaneous conception or infertility treatment at Wayne State University and Detroit
Medical Center facilities. The Institutional Review Board of Wayne State University approved
all consent forms and protocols. Inclusion criteria specified women between 18 and 45 years of
age, 5 to 20 weeks of gestation, both primagravida and multiparous females. Patients with
multiple gestations or experiencing active vaginal bleeding were excluded from the study.
Medical records were reviewed to identify pregnancies with either an uncomplicated outcome
and normal delivery (N=29), or subsequent development of PE or IUGR (N=12). IUGR was
defined as estimated fetal weight less than the 10th percentile for GA [34]. PE was defined as
new onset hypertension (blood pressure >140 systolic or >90 diastolic) and proteinuria (>1+ on a
dipstick or >300 mg/24 h) at or after 20 weeks of gestation [32]. Patient demographics are
summarized in Table 8.
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Table 8. Demographic and obstetric characteristics of the study subjects
Number, n (% of total)
Maternal age in years, median (IQR)
Ethnicity
Caucasian, n (%)
African, n (%)
Asian, n (%)
Hispanic, n (%)
Unknown, n (%)
Gestational age at the time of sampling in weeks,
median (IQR)
Gestational age at delivery in weeks, median (IQR)
Gravity, median (IQR)
Parity
Nulliparous, n (%)
Parous, n (%)
Unknown, n (%)
Delivery mode
Normal Spontaneous Vaginal Delivery (NSVD) ,
n (%)
Cesarean section (CS) , n (%)
Birth Weight (gr), median (IQR)
Sex
Male, n (%)
Female, n (%)
Unknown, n (%)
Adverse pregnancy outcomes, n (%)
IUGR, n (%)
IUGR/sPE, n (%)
sPE, n (%)
Recovered fetal cells
Count, median (IQR)
Fetal/Maternal ratio, median (IQR)
Purity (percentage of βhCG positive cells),
median (IQR)

Control
29 (70)

Adverse
12 (30)

28 ( 24.5‐30)

28.5 ( 24 ‐ 31 )

3 (10)
18 (62)
1 (3)
0 (0)
7 (24)

2 (17)
7 (58)
0 (0)
1 (8)
2 (17)

13 ( 11 ‐ 17 )

13.5 ( 11.25 ‐ 17 )

39 ( 38 ‐ 40 )
2 ( 1 ‐ 3.25 )

37 ( 34.25 ‐ 38 )
3(1‐5)

11 (38)
17 (58)
1 (4)

4 (33)
8 (67)
0 (0)

22 (76)

6 (50)

7 (24)
3082 (2847 ‐ 3521.25)

6 (50)
2402.5 (1900 ‐ 2499)

15 (52)
12 (41)
2 (7)

6 (50)
6 (50)
0 (0)
6 (50)
2 (17)
4 (33)

1030 (712.5 – 1113.7)

529 (460.5 – 928.8)

54E‐5(29E‐5 – 82E‐5)

65E‐5(47E‐5 – 121E‐5)

97.7 (94.9 – 98.9)

96.6 (94.3 – 100)

Maternal age was similar (approximately 28 years old) in both case and control groups. The pathological samples
represented a range of preeclamptic phenotypes (mild to severe), as well as growth restriction (below 10th
percentile). Specimens were obtained at similar gestational ages (median = 13 and 13.5 for control and adverse
cases, respectively). The purity of isolated cells (β-CG-positive) was similarly high in both groups. The ratio of
recovered fetal cells to maternal cells was similar in adverse gestations (median= 65×10-5) compared to controls
(median = 54×10-5).
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Endocervical sampling
Endocervical specimens were obtained, as previously described [58], using a ThinPrep
kit (Hologic, Inc., Marlborough, MA) with cytobrush after placing a speculum in the vagina.
Cervical mucus was included with the specimens. The cytobrush was rinsed into 20 ml of
PreservCyt (Hologic) fixative solution and transported to the laboratory. Mucus was dissolved
by adding 500 μl concentrated glacial acetic acid for 5 min to each specimen. Specimens were
centrifuged at 400 x g for 5 min at 4°C, the supernatant was removed, and the cell pellet was
resuspended in 20 ml of ice-cold sterile PBS. The washing procedure was repeated twice and the
final pellet was resuspended in 10 ml of PBS. To determine the content of trophoblast cells, a
small aliquot of each processed specimen was centrifuged onto a slide using a Shandon Cytospin
3 centrifuge (Thermo-Fisher, Waltham, MA) at 1500 RPM for 5 min and labeled with 10 μg/ml
of mouse anti-HLA-G (Clone 4H84, BD Biosciences, San Diego, CA or Clone G233, Exbio,
Prague, Czech Republic), as previously described [58].
Isolation of trophoblast cells
The TRIC procedure was completed using mouse anti-HLA-G antibody conjugated to
250 nm magnetic nanoparticles (Clemente Associates, Madison, CT), incubating overnight at
4°C in 100 μl sterile PBS with mixing [68].

Using a DynaMag™-Spin magnet (Life

Technologies), the bound and non-bound cells were collected after three washes in 1 ml of PBS.
About 1000 HLA-G-bound cells were recovered from each endocervical specimen (Table 8).
Quality controls for purified EVT cells
TRIC-isolated EVT cells were collected over a 12-month period and archived on slides.
For ICC, small groups of approximately 50 cells were mounted on microscope slides by
cytocentrifugation, inserting the end of a 100 μl (yellow) pipet tip into a Shandon Cytospin
funnel to focus the cells within a 50-μm diameter area to facilitate imaging. The isolated cells
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were 97% positive (for β-hCG:) (Table 8), whereas the depleted cell fraction did not express this
trophoblast marker [68]. It was previously reported that two other trophoblast marker proteins,
KRT7 and placental lactogen (CSH1) are uniformly expressed in the isolated EVT cell fraction
[68]. FISH with probes for the X and Y chromosomes reveals consistent XY or XX labeling of
nuclei in agreement with the sex of babies delivered at the conclusion of pregnancy, verifying the
fetal origin of cells isolated by TRIC [68].
Immunofluorescence labeling
Microscope slides containing either isolated HLA-G-positive cells or recovered HLA-Gdepleted cells were examined, using a standardized and quality controlled immunofluorescence
protocol, and antibodies (see Table 6) raised against β-hCG, KRT7 (DAKO; Carpinteria, CA),
LGALS13, LGALS14, PGF, PAPPA, AFP, ENG, or FLT-1 (R&D Systems). Antibodies were
each titered to ensure a linear fluorescence signal with labeling, (Figure 8) and similar lots of
antibody were used throughout the study. Primary antibody was diluted to 5 μg/ml TTBS/BSA,
and incubated on slides for 17 hrs. at 4°C. Control cells from each specimen were incubated
with 5 μg/ml of non-immune rabbit, goat, rat, or mouse IgG (Jackson ImmunoResearch, West
Grove, PA), as appropriate. Slides were washed three times with TTBS/BSA and incubated for 1
h at room temperature in the dark with similar lots of FITC- or Texas Red-conjugated donkey
anti-mouse, anti-rabbit, anti-rat, or anti goat IgG (Jackson ImmunoResearch), as appropriate,
diluted 1:250 in TTBS/BSA. After slides were washed three times with TTBS/BSA, nuclei were
counterstained with 1 ng/ml of DAPI for 10 min, followed by another three washes with
TTBS/BSA. Slides were cover slipped with Vectashield mounting media (Vector Laboratories,
Burlingame, CA) and sealed with nail polish. β-hCG-positive and negative cells were counted by
fluorescence microscopy, using a Leica DM IRB microscope (Leica Microsystems).
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Protein quantification by image analysis
Antibodies and nuclei were imaged at an objective magnification of 20 × with an
exposure time of 2.0 seconds, using filter sets for DAPI, FITC and Texas Red. Images were
captured with a Hamamatsu Orca cooled-chip digital camera. The FITC or Texas Red stain
intensities were quantified using Simple PCI (Hamamatsu) imaging software. Fluorescence
intensities (grey levels) were determined for each antibody and non-immune IgG (background)
by choosing at least 3 fields per sample and circumscribing minimum of 10 cells per field
resulting in a total of at least 30 cells per sample that were assessed.
The background values were averaged and subtracted from each fluorescent value. The
background-subtracted values for each specimen were averaged to calculate the AFU. Each
AFU value was divided by the average of the AFUs for the control cohort to generate the RFU
values.

Slides were assessed together in a random fashion. KRT7, a trophoblast marker,

provided a technical and biological control for non-specific variances within the sample
populations, assuming it was uniformly expressed in all cells [68]. The expression of KRT7 was
not significantly different in a subset of 13 samples randomly picked from the total population.
Statistical analysis and data modeling
Statistical analyses were performed using JMP (version 10.0; SAS Institute, Cary, NC).
Data were compared using the nonparametric Mann–Whitney U-test to evaluate statistical
differences between groups with significance (p < 0.05).
Cluster analysis was performed and analyzed by BioNumerics (Applied Maths, Austin,
TX, USA), using a hierarchical clustering algorithm with the Unweighted Pair Group Method
with Arithmetic Mean (UPGMA). Recently, this technique has been used to produce clinically
meaningful compact clusters [153]. Number of clusters was determined by dendrograms.
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Results
Table 8 presents the demographic and obstetric characteristics of the study subjects.
Maternal age was similar (approximately 28 years old) in both case and control groups. The
pathological samples represented a range of preeclamptic phenotypes (mild to severe), as well as
growth restriction (below 10th percentile). Specimens were obtained at similar GAs (median =
13 and 13.5 for control and adverse cases, respectively). The purity of isolated cells (β-hCG:positive) was similarly high in both groups. The ratio of recovered fetal cells to maternal cells
was similar in adverse gestations (median= 65×10-5) compared to controls (median = 54×10-5).
Seven candidate biomarkers for adverse pregnancy outcome and the trophoblast-specific
intermediate filament KRT7 were analyzed by standardized immunofluorescence microscopy
and RFUs were calculated. LGALS13 expression was reduced in most adverse cases (Figure
13); however, due to high variability, the difference was not statistically significant (Figure 14).
LGALS14 was notably reduced (median (IQR) = 0.48 (0.22-0.84)) in EVT cells from
pathological pregnancies compared to healthy controls (median (IQR) = 0.93(0.51-1.38))
(Figures 13 & 14). Both PGF and PAPPA were highly expressed (median (IQR) = 1.07(0.301.46) and 0.81(0.48-1.41) respectively) in EVT cells recovered from healthy pregnancies
compared to complicated counterparts (median (IQR) = 0.38(0.30-0.71) and 0.4 (0.22-0.46),
respectively). AFP, FLT1, and ENG were all highly expressed in adverse pregnancies (median
(IQR): 1.76 (1.60-2.06), 2.09 (1.49-2.63), and 2.17 (1.43-3.32), respectively), as compared to the
control group (median (IQR): 0.94 (0.62-1.26), 0.92 (0.55-1.19, and 0.92 (0.33-1.59),
respectively) (Figures 13 & 14). Levels of KRT7 were similar (p=0.85) in both groups (Figure
14), supporting the specificity of these findings.
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“
Figure 13: Representative fluorescence microscopic images of EVT cells obtained by TRIC
from control and adverse pregnancies. Paired images are shown for fields of cells labeled with
DAPI or by immunofluorescence for the proteins, as indicated. (scale bars = 100 μm)
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Figure 14: Box-and-whisker plot showing the distribution of normalized RFU values of
each candidate protein biomarker for control (white boxes) and adverse outcome (black
boxes) patients. The boxes represent the 25th to 75th percentiles, and horizontal lines within the
boxes indicate the medians. The whiskers are drawn to indicate 1.5 × Inter Quartile Range (3rd
quartile – 1st quartile). The triangles represent outliers.
Despite the diversity of clinical phenotypes generated by uteroplacental insufficiency, the
selected biomarkers successfully identified two main clusters; one containing 67% adverse
pregnancy outcomes (Cluster 2), and the other with 92% healthy pregnancies (Cluster 1), with
minimum similarities of 68.7% and 68%, respectively (Figure 15). In this model, Cluster 1,
which mostly includes healthy samples (92%), contains two major sub-clusters with two distinct
biomarker expression patterns.

One is characterized by over-expression of LGALS13,

LGALS14, PAPPA and PGF (1a), and the other is described by under-expression of all protein
candidates (1b; Figure 15).
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Figure 15: Hierarchical clustering analysis identifying two major clusters identified as
Cluster 1 and Cluster 2. Cluster 1 was further subdivided into two sub-clusters (1a, 1b) with
distinguishable expression patterns. A subgroup of three control pregnancies showing an
''extreme" normal profile clustered separately at the top of the chart, and have a high degree of
similarity (78.8%).
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The predictive RFU value for each biomarker was determined by performing the ROC
analysis. The results support the findings of the nonparametric comparisons between groups
(Figure 14), and reveal that each individual protein (except LGALS13) discriminated healthy
from adverse pregnancies (Table. 9). AFP correlates best with adverse pregnancies, based on the
highest sensitivity, specificity and positive likelihood ratio (100, 86.21 and 7.25 respectively).
To test whether a combination of factors correlates better with pregnancy outcome, a series of
ROC curves was generated for combinations of biomarkers, and the areas under the curves
(AUCs) were calculated and plotted (Figure 16). The highest AUC (0.948) was achieved with
all markers present in the model. A four-marker combination (e.g., LGALS13, LGALS14, PGF
and FLT1) had similar sensitivity and specificity (AUC = 0.948; Figure 16, red arrow).
Table 9. Receiver operating characteristic curve analysis and diagnostic performances of
the protein markers

The Likelihood Ratios (LRs) were calculated to evaluate the clinical usefulness of factors for prediction. AFP was
the most compelling factor among candidates for prediction of adverse gestations, based on its +LR. FU,
Flourescence Unit; +LR, Positive likelihood ratio; -LR, Negative likelihood ratio; CI, Confidence interval, * p <
0.05.
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Figure 16: Receiver operating characteristic curve analysis of biomarker combinations.
The area under the curve (AUC) was calculated to evaluate the accuracy of the tests with all
possible combinations of candidate markers. The values were visualized as a histogram. Each bar
represents the estimated AUC for one set from the combination matrix, represented below. In the
matrix, the inclusion of the protein markers in each combination set was illustrated by bold color.
Among the last 8 sets with equally high AUC=0.948 (highlighted in grey), a 4-factor (LGALS13,
LGALS14, PGF, FLT1) test was nominated as the most cost-effective composite with highest
sensitivity and specificity (red arrow).
Discussion
Real-time, non-invasive assessment of EVT cells in ongoing pregnancies is now possible
beginning at five weeks of pregnancy, using TRIC. The present study, for the first time, assessed
and documented the association between the protein expression profile of cervical EVT cells
recovered by TRIC and pregnancy outcome.
Histological examination of placentas delivered by women with PE and IUGR suggests a
prior disruption of (EVT) function in the first trimester that predisposes to uteroplacental
insufficiency, characterized by reduced trophoblast invasion, insufficient remodeling of the spiral
arteries, and elevated EVT cell death [74, 76, 77, 144]. Although it is thought that remodeling of
the uterine arteries becomes deficient before PE and IUGR are diagnosed, direct evidence of
early EVT dysfunction is lacking and the underlying etiologic cellular and molecular
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mechanisms are unknown.

Galectin-13 (LGALS13/PP13) and LGALS14 are among the

placenta-specific galectins of mammals [129]. The observed lower expression of both galectins
in pathological EVT cells accords with their significant decrease in maternal serum during the
first trimester in women who later develop early-onset PE [114, 154]. Serum markers used to
screen for aneuploidy (AFP and PAPPA) were also altered in EVT fetal cells from pathologic
pregnancies, supporting the reliability of these factors for early prediction of pregnancies at risk
for IUGR and PE shown in previous reports [155-157]. Interestingly, Chapter 3, we found
comparable protein marker expression patterns in EPL suggesting a common EVT phenotype of
severe placental insufficiency.
There is encouraging evidence for the utility of circulating sFLT1, sENG and PGF as
biomarkers several weeks before clinical signs of PE appear [158-161]. In the second stage of
disease progression, anti-angiogenic factors accumulate in maternal blood, particularly soluble
splice variants of FLT1 and ENG [142]. Pro-angiogenic proteins, like PGF, are reduced, and
receptor binding is antagonized by sFLT1. Both serum biomarker screening and uterine artery
Doppler ultrasound have been explored for prediction of uteroplacental insufficiency before
maternal disease appears [162, 163]. Screening the protein levels of these markers in EVT cells
from first and second trimester pregnancies revealed significant alterations, either increasing
(FLT1 and ENG) or decreasing (PGF) in pregnancies that later developed PE or IUGR (Figure
13 & 14), similar to the trends described in maternal serum [158]. Overall, we revealed that the
individual expression patterns of candidate biomarkers for adverse pregnancy outcomes in EVT
cells recapitulated what has been described in serum at later stages of disease, suggesting that the
EVT phenotype is established very early in pregnancy.
Clustering analysis demonstrated that, within the population of patients studied, 79% of
the healthy pregnancies (N=23) partitioned into a distinct group composed of 92% with
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uncomplicated outcomes (Figure 15). These findings confirm that the altered maternal serum
levels of these seven proteins observed in women who develop PE or IUGR reflect changes in
the EVT cells. PE and IUGR are syndromes with complex etiologies that are not strictly the
result of uteroplacental insufficiency [101]. Therefore, it is not surprising that two adverse
pregnancies partitioned with the cluster of mostly normal pregnancies and five normal cases
were distributed throughout the cluster that contained 67% adverse outcomes. These apparent
misplacements could result from limitations of the biomarker analyses, or reflect uteroplacental
insufficiency that did not culminate in clinical disease. Doppler ultrasonographic data was not
available to investigate further.
First trimester screening of multiple predictors is currently uninformative even when
combined in a multivariable model [143].

The inability to recognize pathologies of

uteroplacental insufficiency early in pregnancy, before overt clinical symptoms arise, has been
linked to limitations in current non-invasive interrogation of the placenta [1].

EVT cells

obtained through TRIC provide a non-invasive tool to investigate the expression of candidate
protein biomarkers and their relationship to pregnancy outcome. Beyond the direct health
benefits for mothers and babies at risk, the development of valid biomarkers to identify healthy
pregnancies could foster personalized prenatal care and channel resources towards the treatment
of high-risk pregnancies.
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CHAPTER V
TRIC: NON-INVASIVE PRENTAL TESTING UNAFFECTED BY EARLY
GESTATIONAL AGE OR BMI
Introduction
Trophoblast cells are shed from the placenta into the lower uterine segment, and can be
retrieved from the cervix as early as 5 weeks GA [49, 164]. Multiple investigators have obtained
trophoblast cells from the cervix of ongoing pregnancies and evaluated their use for non-invasive
prenatal testing (NIPT), including detection of trisomies 18 and 21, Rh fetal status in Rh negative
mothers, and hemoglobinopathies [63-67].

We identified trophoblast cells in endocervical

specimens as early as 5 weeks GA with a monoclonal antibody against HLA-G [58], a protein
present on trophoblast cells and not on maternal cervical cells [69]. A significant decrease in the
proportion of trophoblast/cervical cells was found in samples collected between 6-20 weeks GA
from patients with an ectopic pregnancy or blighted ovum, as compared to healthy term
pregnancies.

It was speculated that trophoblast yield could predict abnormal pregnancies,

although the sample number was small.
A limiting feature of using trophoblast cells obtained from the cervix for NIPT was the
inability to efficiently isolate the fetal cells from an excess of maternal cervical cells. We
recently developed TRIC, a safe procedure to obtain trophoblast cells from the cervix with a high
degree of purity in ongoing pregnancies, using HLA-G for immunomagnetic isolation [68].
TRIC can reliably identify fetal gender as early as 5 weeks GA by fluorescence in situ
hybridization or the polymerase chain reaction (PCR) [68]. The isolated cells are intact as
evidenced by the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay.
Additionally, ICC characterization indicates that the cells obtained by TRIC are of the EVT
phenotype.
NIPT in current clinical practice utilizes circulating cell-free fetal DNA obtained from
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maternal plasma, which is adversely affected by early GA and maternal obesity [165].
Additionally, NIPT using cell-free fetal DNA cannot ensure the presence of an intact fetal
genome, particularly at early GA, limiting its diagnostic value [45]. Initial studies suggest that
early GA does not negatively impact TRIC [58, 68]; however, its limitations are not well
understood. In the present study, we evaluated whether early GA, maternal obesity, parity,
maternal age, and pregnancy outcomes adversely affect trophoblast yield during TRIC.
Materials and Methods
Patient selection
Trophoblast cells were collected and isolated by TRIC in an ongoing study, from which
224 patients were enrolled between 2011 and 2014. Medical records were evaluated to obtain
maternal age, GA at time of retrieval, maternal body mass index (BMI), and parity, as well as
uncomplicated pregnancies with full term deliveries, and pregnancies with complications,
including PE, IUGR, or EPL. PE was defined as new onset proteinuria and elevated blood
pressure after 20 weeks GA [32], and IUGR was defined as birth weight below the 10th
percentile for GA [34]. The Institutional Review Board of Wayne State University approved the
study, and each subject provided written informed consent prior to participation. The inclusion
criteria included pregnant women between the ages of 18 and 45, and a GA from 5 to 20 weeks.
Exclusion criteria included women who were experiencing active vaginal bleeding and
pregnancies with multiple gestations. GA was determined by the date of the last menstrual
period and first ultrasound.
Endocervical sampling
Endocervical samples were obtained as described previously [68]. Briefly, a speculum
was inserted into the vagina and endocervical samples were collected using a cytobrush and a
ThinPrep Kit (Hologic, Inc., Marlborough, MA) containing 20 ml of PreservCyt fixative
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solution. The specimens were transferred to the laboratory, where they were acidified with 500
μl of glacial acetic acid for 5 minutes to dissolve the mucous. Samples were centrifuged at 400 x
g for 5 minutes at 4°C. The supernatant was removed and the cell pellet was re-suspended in 20
ml of ice-cold sterile PBS. Specimens were then washed by centrifugation and re-suspended two
more times with 20 mL of PBS, and on the final wash, the volume was brought to 10 mL with
PBS at 4°C.
Isolation of trophoblast cells
The endocervical specimens were centrifuged and re-suspended in 1 ml PBS, combined
with mouse anti-HLA-G antibody conjugated to 250 nm magnetic nanoparticles (Clemente
Associates, Madison, CT), and incubated overnight at 4°C with mixing. The EVT cells bound to
magnetic nanoparticles were then immobilized on a DynaMag-Spin magnet (Life Technologies)
for 10 minutes. The non-bound cells were collected, followed with three washings in 1 ml of
PBS. The bound trophoblast cells were counted and checked for purity by ICC labeling of the
trophoblast marker, human β-hCG. Purity is reported as percentage of cells labeled with β-hCG
(trophoblast cells) versus total cells (DAPI), as described previously [68].
Statistical analysis
The trophoblast yield data were subjected to a natural log transformation (ln) prior to
subsequent analysis, because the data were not normally distributed. The non-parametric MannWhitney-Wilcoxon Test (binomial) or the Kruskal Wallis Test (ordinal values) was employed for
comparison.

Linear regression was used to examine the association of log-transformed

trophoblast yield and other variables. p values <0.05 were considered statistically significant.
All statistical computations were performed using the open-source R software (www.rproject.org/).
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Results
The median trophoblast yield from all 224 specimens evaluated was 675 (IQR, 399-1010)
cells, and the median purity based on β-hCG staining was 97.9% (IQR 93.3-100) (Figure _17).
Trophoblast cells were isolated between 5 and 20 weeks GA, with 42.9% prior to 10 weeks GA.
Median GA, BMI, parity, and maternal age were 11 weeks (IQR 8-15), 28.6 (IQR 23.7-37.1), 1
(IQR 0-2), and 26 years of age (IQR 22-30), respectively. There was no correlation between
GA, BMI, parity, or maternal age and trophoblast yield (Figure 18).

Figure 17: Assessment of trophoblast purity by β-hCG expression. Isolated trophoblast cells
labeled with anti-β-hCG were examined by immunofluorescence microscopy. Image on the left
represents β-hCG staining, and the image on the right represents DAPI staining of the same field
of cells. (scale bar = 100 μm)
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Figure 18: Correlation between trophoblast yield (log transformed) and GA, maternal
BMI, parity, and maternal age. The number of isolated trophoblast cells was correlated to GA
(A), maternal BMI (B), parity (C), and maternal age (D), using linear regression. No significant
correlations were found.
Among the 224 patients, 113 were either uncomplicated term outcomes (n=75), or
pregnancies with adverse outcomes (n=38), including PE and/or IUGR (n=20), and EPL (n=18).
Although the trophoblast yield in adverse outcomes compared to the healthy control cohort was
decreased (median= 510 (IQR 250-786) vs. 750 (IQR 400-1020), it did not reach statistical
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significance (p=0.052; Figure 19). Sub-analysis of the adverse cohort revealed a significant
decrease (p <0.05) in trophoblast yield in the EPL cohort (median = 407 (IQR 227-572))
compared to the healthy cohort (Figure 19), but in the PE/IUGR cohort (median= 530 (IQR 3871050) no significance was found (p= 0.674). Median purity of the EVT cells obtained in the
healthy cohort group, EPL, and IUGR/PE groups were 98% (IQR 93.2-100), 95.7% (IQR 92.2100) and 97.7% (IQR 95.1-100), respectively.
A)

B)

Figure 19: Trophoblast yield (log transformed) was compared to pregnancy outcome.
Trophoblast yield obtained by TRIC was compared in pregnancies with adverse outcomes (N=
38), including PE, IUGR, and EPL to pregnancies with uncomplicated term deliveries (N= 75).
Statistical analysis was performed with the Kruskal Wallis test. A. There was no significant
difference in trophoblast yield in pregnancies with adverse outcomes (PE, IUGR, and EPL)
compared to uncomplicated term controls. B. Further subdividing the adverse group into
PE/IUGR (N=20) and EPL (N=18) revealed a significant decrease (p<0.05) in the EPL cohort
compared to the control cohort (N=75). Boxes represent 25th to 75th percentiles, horizontal lines
within boxes represent the median, bars are 1.5x IQR. The diamonds represent outliers. Samples
labeled above with different letters are significantly different.
Discussion
Currently, prenatal genetic testing relies on invasive methods such as chorionic villous
sampling or amniocentesis to acquire fetal tissue. Although these methods are reliable for
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genetic diagnosis, the earliest they can be performed is 10 weeks GA with a fetal loss risk of
approximately 0.5% [44]. NIPT using cell-free fetal DNA is widely available for prenatal
genetic screening after 10 weeks GA, but is negatively impacted by GA and obesity [45, 166].
Currently, cell-free fetal DNA cannot be used diagnostically, and results should be confirmed by
invasive testing [48]. TRIC can isolate intact fetal cells [68], and could provide a minimallyinvasive, alternative approach to NIPT. The present study reveals that trophoblast yield obtained
by TRIC is as robust at 5 weeks as 20 weeks GA. Furthermore, TRIC is unaffected by maternal
obesity, parity or age.
We found a significant decrease in trophoblast cells isolated from pregnancies with EPL
compared to pregnancies with healthy term deliveries.

In a previous report, we found a

significant decrease in trophoblast cells from crude cervical smears in pregnancies with a
blighted ovum, compared to successful intrauterine pregnancies [58]. We are aware that the total
number of cells per specimen varies, which would influence trophoblast yield. Nevertheless, our
data confirm previously published results analyzing both adverse outcome and GA in which
trophoblast yield was normalized to total cell number [58].
Abnormal placentation, as observed in EPL, PE and IUGR, is characterized by increased
trophoblast apoptosis and shedding [167], releasing fetal DNA fragments into the maternal
circulation [168-170]. Here, we show decreased numbers of trophoblast cells migrating to the
cervix in pregnancies with adverse outcomes, reflecting the abnormal placentation associated
with these pathologies.
TRIC provides for the first time intact fetal cells in adequate numbers for downstream
molecular and genetic testing without a negative impact of GA or BMI. The current study
provides the foundation for future validation of TRIC for NIPT.

63
CHAPTER VI
EXTRAVILLOUS TROPHOBLAST CELLS OBTAINED BY TROPHOBLAST
RETRIEVAL AND ISOLATION FROM THE CERVIX (TRIC) EXHIBIT LOW RATES
OF MOSAICISM AND ACCURATELY PREDICT GENDER
Introduction
The risk of having a newborn infant with a chromosomal abnormality or structural defect
has been estimated to be approximately 3%-5% [43]. The most common methods for PGD, are
CVS and amniocentesis, which at earliest can be performed at 10 and 15 weeks GA,
respectively; both methods are invasive with a fetal loss risk of approximately 0.5%-1.0% [44].
Maternal plasma cell free fetal DNA, has become widely available as a prenatal genetic
screening test, however, it is not without its limitations. The earliest it is currently available is 10
weeks GA and it does not isolate an intact fetal genome, which limits its diagnostic capabilities
[45]. Therefore, it is recommended that testing with circulating cell free fetal DNA only be
offered to patients at high risk of aneuploidy, and that an abnormal test be followed up with a
confirmatory invasive test [171]. An alternative non-invasive test that can isolate intact fetal
cells prior to 10 weeks GA would be of great clinical value.
Trophoblast cells are shed into the lower uterine segment during pregnancy and can be
retrieved from the cervix as early as 5 weeks GA [49, 68, 164]. Multiple investigators have
identified trophoblast cells in cervical smears from ongoing pregnancies and have investigated
the use of these cells for PGD, identifying fetuses affected by trisomies 18 and 21, sickle cells
disease, and even hemoglobinopathies [63, 65-67, 172]. The rate-limiting step in using these
cells as an alternative form of non-invasive PGD was the inability to efficiently isolate
trophoblast cells with a high degree of purity from maternal cervical cell contaminants.
TRIC is a new innovated technique that efficiently isolates trophoblast cells apart from
maternal cervical cell with a high degree of purity, using immunomagnetic isolation as early as 5
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weeks GA [68]. By taking advantage of HLA-G, a cell surface protein present on trophoblast
cells and not on cervical cells [69], trophoblast cells can be efficiently isolated form cervical
cells with purities over 95% [68]. Using TRIC, we have demonstrated the ability to accurately
predict gender by FISH and PCR. Furthermore, we have shown that the isolated cells have the
extravillous phenotype and contain intact nuclear DNA [68].
Despite these promising findings, studies have suggested that extravillous trophoblast
cells (EVT) exhibit a high degree of aneuploidy [70, 71]. However, FISH accurately detected
trisomy 21 in fetal cells obtained from endocervical specimens, and demonstrated its absence in
all specimens from normal pregnancies [65]. Based on the latter report, we hypothesize that the
karyotype of EVT cells obtained by TRIC accurately reflects that of the fetus. Using FISH, we
examined the rates of mosaicism in chromosomes 13, 18, 21, X, and Y of EVT cells isolated by
TRIC from normal ongoing pregnancies.
Materials and Methods
Patient selection
Trophoblast cells were obtained by TRIC from 41 pregnant patients (27 with male fetuses
and 14 with female fetuses) between 5 and 20 weeks GA. The Institutional Review Board of
Wayne State University approved the study and each subject provided written informed consent
prior to participation. The inclusion criteria were pregnant women between the ages of 18 and
45, and GA from 5 to 20 weeks. Exclusion criteria included women who were experiencing
active vaginal bleeding. GA was determined by the date of the last menstrual period and first
ultrasound. Gender of the fetus was determined by fetal ultrasound or birth records.
Endocervical sampling
Endocervical specimens were obtained as previously described [68]. Briefly, a speculum
was inserted into the vagina and endocervical cells were collected using a cytobrush and a
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ThinPrep Kit (Hologic, Inc., Marlborough, MA) with 20 ml of PreservCyt fixative solution. The
specimens were then transferred to the laboratory and were acidified with 500 μl of glacial acetic
acid for 5 minutes to dissolve the mucous. Samples were centrifuged at 400 x g for 5 minutes at
4°C. The supernatant was removed and the cell pellet was re-suspended in 20 ml of ice-cold
sterile PBS. Specimens were washed by centrifugation and re-suspended two more times with
20 ml of PBS and on the final wash were brought to 10 ml with PBS at 4°C.
Trophoblast cell isolation
The endocervical specimens were centrifuged and re-suspended in 1.0 ml of PBS and
then combined with mouse anti-HLA-G antibody conjugated to 250 nm magnetic nanoparticles
(Clemente Associates, Madison, CT). The suspension was incubated overnight at 4°C with
mixing. The EVT cells bound to magnetic nanoparticles were then immobilized on a DynaMagSpin magnet (Life Technologies) for 10 minutes. Non-bound cells were collected, followed with
three washings in 1 ml of PBS. Bound trophoblast cells were counted and checked for purity by
ICC using of the trophoblast marker, human chorionic gonadotropin β- subunit (β-hCG). Purity
is reported as percentage of cells labeled with β-hCG (trophoblast cells) versus total cells
(DAPI), as described previously [68].
Fluorescence in situ hybridization
Aliquots of approximately 20-50 isolated trophoblast cells and isolated maternal cervical
cells were spun onto a 1 mm diameter area of a microscope slide, using a Shandon Cytospin 3
centrifuge (Thermo-Fisher, Waltham, MA) at 1500 RPM for 5 min. FISH was performed at the
Detroit Medical Center Cytogenetics Laboratory using the AneuVysion FISH kit (Abbott
Molecular). The slides were immersed in 100 ml of 0.11 mg/ml pepsin in 0.01 N HCl for 10 min
at 37±1ºC. Slides were then washed once in PBS for 5 minutes at room temperature and fixed
within 1% formaldehyde for 5 minutes at room temperature. Slides were then washed in PBS for
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5 minutes at room temperature, and dehydrate by immersing them into a 70%, 85%, and 100%
ethanol series at room temperature for 1 minute each. Slides were allowed to dry completely and
hybridized with AneuVysion probe sets (3 µl of each probe) at a denaturation temperature of
75°C for 5 minutes, followed by hybridization at a temperature of 37°C for 16-20 hours. Slides
were

then

washed

in

0.4X

saline-sodium

citrate

(SSC)

containing

0.3%

nonyl

phenoxypolyethoxylethanol (NP-40) at 73±1°C for 2 min, then 2XSSC/0.1%NP-40 at room
temperature for 2 minutes. Cells were counterstained with 3 µl of DAPI. Using an Olympus
BX51 epi-fluorescence microscope equipped with a 120-watt OEX bulb, slides were analyzed
using dual orange/green bandpass, single aqua bandpass, and DAPI bandpass filters. Number of
signals for chromosomes 13, 18, 21, X, and Y, were then counted and recorded for each nucleus.
Slides were first probed for chromosomes 18, X and Y, and then rehybridized with probes for
chromosomes 13, and 21.
Statistical analysis
Diploid rates were calculated by dividing the number of cells that were diploid by the
total number of cells analyzed. Average diploid rates for each chromosome were calculated by
averaging the average diploid rates for all patients for each chromosome analyzed. Comparison
of diploid rates between fetal and maternal samples were calculated by Mann-Whitney-Wilcoxon
test due to non-normal distribution, with p<0.05 indicating significance. The extremely left
skewed data (trophoblast yield) was subjected to a natural log transformation (ln) before
subsequent analysis. Correlation between GA and either trophoblast yield or diploid rates were
calculated by Spearman's rank correlation coefficient (rho). All statistical computations were
performed using the open-source R software (www.r-project.org/).
Results
TRIC samples were analyzed from a total of 41 patients, of which 27 were carrying a
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male fetus and 14 were carrying a female fetus (Table 10). Average purity by β-hCG staining,
GA at time of collection, and trophoblast yield ± standard error of the mean (SEM) were 94.2%
± 1.2%, 13.1 ± 0.6 weeks, and 740.8 ± 92.9 cells. Gestational age at time of collection ranged
from 5w2d to 19w5d (Table 10). β-hCG purity was unavailable for seven male specimens;
however, purity of their EVT isolation was evaluated by percentage of cells staining for the Y
chromosome. There was no correlation between GA and trophoblast yield (p = 0.267).
On average, the total number of fetal cells evaluated per patient for chromosomes 13, 18,
21, X/Y were 23.0 ± 2.3, 29.2 ± 2.1, 23.0 ± 2.3, and 29.2 ± 2.5 cells, respectively. The diploid
rates in EVT cells for chromosomes 13, 18, 21, X/Y were 95.4 ± 2.3%, 93.4 ± 2.38%, 88.1±
1.96%, and 97.8± 0.57%, respectively (Tables 11, 12, 13, 14, 15, 16). In the cohort of 27
patients with known male fetuses, the percentage of cells staining positive for X/Y were 96.9% ±
1.5% (Table 15). Figure 20 contains fluorescent images of selected FISH samples.
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Table 10. List of specimens used in analysis of aneuploidy by FISH.
G.A

Trophoblast Yield

Purity (%β-hCG
Positive)

Sex

5w2d
6w
7w
7w4d
7w5d
7w5d
7w6d
8w6d
9w
9w2d
10w2d
11w2d
11w3d
12w
12w3d
12w4d
12w5d
12w6d
13w3d
13w3d
13w4d
13w5d
14w
14w
14w1d
14w1d
14w2d
15w
15w
15w3d
15w5d
16w1d
17w2d
17w2d
18w
18w
18w1d
18w2d
18w5d
19w3d
19w5d

835
1382
110
1400
885
490
500
720
450
1190
508
1535
575
1125
900
1107
38
2620
400
290
50
640
1514
1485
130
153
50
465
324
150
980
630
100
610
50
360
1050
2100
1821
50
600

100
100
89
92
95.8
97
100
100
93
90
95.8
66.7
98
100
85.7
94.7
N/A
100
100
97.1
N/A
89.1
98
99
88
83.7
N/A
100
98.8
N/A
85.7
100
96.5
N/A
88.9
89.4
100
100
91.3
N/A
N/A

M
M
M
M
F
M
F
F
M
M
M
F
F
M
M
F
M
M
M
M
M
M
M
F
M
F
M
F
F
M
M
F
M
M
F
F
F
M
M
M
M

GA correlates to GA during which TRIC was performed. Trophoblast yield correlates to
number of EVT cells isolated by TRIC. EVT purity correlates to percentage of isolated
trophoblast cells staining positive for β-hCG. Sex correlates to the confirmed sex of fetus
(M=male, F=female). w=weeks, d=days.
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Table 11. Percentage of diploid cells by FISH of EVT cells obtained by TRIC
Chromosome

Percent Monosomy

Percent Diploid

Percent Trisomy

Percent Tetrasomy

13
18
21
X/Y

3.5% ± 0.20%
5.8% ± 0.24%
2.39% ± 0.13%
1.2% ± 0.27%

95.4% ± 2.3%
93.4% ± 2.38%
88.1% ± 1.96%
97.8% ± 0.57%

0.53% ± 0.08%
0.25% ± 0.05%
8.6% ± 0.93%
0.42% ± 0.12%

0.43% ± 0.06
0.50% ± 0.10%
0.98% ± 0.12%
0.48% ± 0.23%

Percentages are mean ± SEM

Table 12. EVT chromosome 13 ploidy rates examined by FISH
GA
5w2d
6w
7w
7w4d
7w5d
7w5d
7w6d
8w6d
9w
9w2d
10w2d
11w2d
12w
12w3d
12w4d
12w5d
12w6d
13w3d
13w3d
13w4d
13w5d
14w
14w
14w1d
14w1d
14w2d
15w
15w
15w3d
15w5d
16w1d
17w2d
17w2d
18w
18w
18w1d
18w2d

Monosomy
2
0
0
0
3
2
2
0
2
1
0
0
0
0
1
5
0
0
1
4
3
2
0
1
0
1
0
0
0
0
0
0
0
0
0
0
2

Diploid
34
20
28
10
23
48
33
2
18
23
50
8
5
28
22
25
7
25
20
3
28
28
33
5
15
18
17
68
13
13
39
27
4
14
18
5
8

Trisomy
0
0
0
0
0
0
0
0
0
3
0
0
0
0
1
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Tetrasomy
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
1
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0

Total
36
20
28
10
26
50
35
2
20
27
50
8
5
28
24
32
7
25
21
7
33
31
33
6
15
19
17
68
13
13
40
27
4
14
18
5
10

% Diploid
94.4%
100
100
100
88.5
96.0
94.3
100
90.0
85.2
100
100
100
100
91.7
78.1
100
100
95.2
42.9
84.9
90.3
100
83.3
100
94.7
100
100
100
100
97.5
100
100
100
100
100
80.0

70
18w5d
0
22
0
0
22
100
19w3d
0
50
0
0
50
100
19w5d
0
22
0
0
22
100
Total
32
879
6
4
921
Average
3.47%
95.4%
0.65%
0.43%
23.0
94.7%
Ploidy rates for EVT cells obtained by TRIC from 40 patients were evaluated by FISH. GA represents GA at
time of collection. An average of 23.0 cells per patient was evaluated. Diploid rates were 95.7% (total diploid
cells divided by total cells evaluated) and 94.7% (average of all diploid rates). w=weeks, d-days.

Table 13. EVT chromosome 18 ploidy rates examined by FISH
GA

Monosomy

Diploid

Trisomy

Tetrasomy

Total

% Dipolid

5w2d
6w
7w
7w4d
7w5d
7w5d
7w6d
8w6d
9w
9w2d
10w2d
11w2d
11w3d
12w
12w3d
12w4d
12w5d
12w6d
13w3d
13w3d
13w4d
13w5d
14w
14w
14w1d
14w1d
14w2d
15w
15w
15w3d
15w5d
16w1d
17w2d
17w2d
18w
18w
18w1d
18w2d
18w5d

1
2
1
4
0
3
2
0
2
2
0
0
2
1
2
2
4
1
0
3
1
3
2
2
3
4
3
0
3
0
0
1
4
0
2
0
0
1
6

49
13
24
14
40
47
34
5
18
31
35
8
11
15
42
31
35
13
25
15
5
17
25
48
47
46
34
12
57
13
13
39
44
7
40
28
6
17
44

0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0

50
15
25
18
40
50
36
5
20
33
35
8
13
16
50
33
39
14
25
19
6
20
27
50
50
50
37
12
60
13
13
40
50
7
42
28
6
18
50

98.0
86.7
96.0
77.8
100
94.0
94.5
100
90.0
93.9
100
100
84.6
93.8
84.0
93.9
89.7
92.9
100
78.9
83.3
85.0
92.6
96.0
94.0
92.0
91.9
100
95.0
100
100
97.5
88.0
100
95.2
100
100
94.4
88.0

71
19w3d
0
50
0
0
50
100
19w5d
3
23
0
0
26
88.5
Total
70
1120
3
6
1199
Average
5.83%
93.4%
0.25%
0.50%
29.2
93.4%
Ploidy rates for EVT cells obtained by TRIC from 41 patients were evaluated by FISH. GA represents GA at
time of collection. An average of 29.2 cells per patient was evaluated. Diploid rates were 93.4% (total diploid
cells divided by total cells evaluated) and 93.4% (average of all diploid rates). w=weeks, d-days.

Table 14. EVT chromosome 21 ploidy rates examined by FISH
GA

Monosomy

Diploid

Trisomy

Tetrasomy

Total

% Diploid

5w2d
6wk
7wk
7w4d
7w5d
7w5d
7w6d
8w6d
9wk
9w2d
10w2d
11w2d
12wk
12w3d
12w4d
12w5d
12w6d
13w3d
13w3d
13w4d
13w5d
14wk
14wk
14w1d
14w1d
14w2d
15wk
15wk
15w3d
15w5d
16w1d
17w2d
17w2d
18wk
18wk
18w1d
18w2d
18w5d
19w3d
19w5d
Total

1
0
0
0
0
2
1
0
2
0
0
0
0
0
1
2
0
0
1
2
1
0
2
0
0
3
0
1
1
1
0
0
0
0
0
0
1
0
0
0
22

34
20
28
10
26
48
34
2
18
27
22
8
5
28
20
28
7
25
11
4
31
31
26
6
15
16
17
41
12
11
40
27
4
17
18
5
9
8
50
22
811

1
0
0
0
0
0
0
0
0
0
24
0
0
0
1
2
0
0
6
0
1
0
5
0
0
0
0
26
0
0
0
0
0
0
0
0
0
13
0
0
79

0
0
0
0
0
0
0
0
0
0
4
0
0
0
0
0
0
0
2
1
1
0
0
0
0
0
0
0
0

36
20
28
10
26
50
35
2
20
27
50
8
5
28
22
32
7
25
20
7
34
31
33
6
15
19
17
68
13
12
40
27
4
17
18
5
10
22
50
22
921

94.4
100
100
100
100
96.0
97.1
100
90.0
100
44.0
100
100
100
90.9
87.5
100
100
55.0
57.1
91.2
100
78.8
100
100
84.2
100
60.3
92.3
91.7
100
100
100
100
100
100
90.0
36.4
100
100

0
0
0
0
0
0
0
1
0
0
9
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Average
2.39%
88.1%
8.58%
0.98%
23.0
90.9%
Ploidy rates for EVT cells obtained by TRIC from 40 patients were evaluated by FISH. GA represents GA at
time of collection. An average of 23.0 cells per patient were evaluated. Diploid rates were 88.1% (total
diploid cells divided by total cells evaluated) and 90.9% (average of all diploid rates). w=weeks, d-days.

Table 15. EVT cells obtained by TRIC from known male fetuses examined by FISH
GA

XX

XY

Aneuploid

Total

% X/Y

5w2d
0
49
0
49
100%
6w
3
10
1
14
71.4%
7w
0
25
0
25
100%
7w4d
0
18
0
18
100%
7w5d
0
40
0
40
100%
9w
0
20
0
20
100%
9w2d
2
31
0
33
93.9%
10w2d
0
35
0
35
100%
12w3d
0
47
3
50
94%
12w3d
3
13
1
17
76.5%
12w5d
0
38
1
39
97.4%
12w6d
0
13
0
13
100%
13w3d
0
20
1
21
95.2%
13w3d
0
25
0
25
100%
13w4d
1
5
0
6
83.3%
13w5d
1
18
1
20
90%
14w
0
27
0
27
100%
14w1d
0
50
0
50
100%
14w2d
0
37
0
37
100%
15w3d
1
12
1
14
85.7%
15w3d
0
13
0
13
100%
17w2d
0
48
2
50
90%
17w2d
1
6
0
7
85.7%
18w2d
0
18
0
18
100%
18w5d
0
50
0
50
100%
19w3d
0
50
0
50
100%
19w5d
0
26
1
27
96.3%
Total
12
744
12
768
Average
1.56%
96.9%
1.56%
28.4
95%
First column depicts GA at time of collection. X/Y diploid rates were 96.9% (total diploid
cells divided by total cells evaluated) and 95.0% (average of all diploid rates). w=weeks, ddays.

Table 16. EVT cells obtained by TRIC from known female examined by FISH
GA

XX

XY

Aneuploid

Total

% Diploid

7w5d
7w6d
8w6d
11w2d
11w3d
12w4d
14w
14w1d
15w

49
36
5
8
11
33
48
47
12

0
0
0
0
0
0
0
0
0

1
0
0
0
2
0
2
2
0

50
36
5
8
13
33
50
49
12

98%
100%
100%
100%
84.6%
100%
96%
95.9%
100%

73
15w
52
0
8
60
86.7%
16w1d
39
0
1
40
97.5%
18w
42
0
0
42
100%
18w
28
0
0
28
100%
18w1d
6
0
0
6
100%
Total
416
0
16
432
Average
96.3%
0
3.7%
30.9
97%
First column depicts GA at time of collection. X/X diploid rates were 96.3% (total diploid
cells divided by total cells evaluated) and 97.0% (average of all diploid rates). w=weeks, ddays.

Figure 20: Selected EVT FISH images. For chromosomes 18/X/Y images, chromosome 18 is
stained with spectrum aqua, chromosome X is stained with spectrum green, and chromosome Y
with spectrum orange. For chromosomes 13/21, chromosome 13 is stained with spectrum green
and chromosome 21 with spectrum orange. A, B, and C Diploid 18/X/Y. D and E, diploid
18/XX. F, diploid 13/21. G, diploid 13/trisomy 21. H, monosomy 18, X/Y. I, trisomy 13.
The majority of aneuplodies observed in EVT cells were monosomies for chromosomes
13, 18, and X/Y with 3.5% ± 0.20%, 5.8% ± 0.24%, and 1.,2% ± 0.27%, respectively; whereas
for chromosome 21, the most frequent aneuploidy was trisomy with a rate of 8.6% ± 0.93%.
There was no correlation between GA and diploid rates for all chromosomes examined (Figure
21).
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Figure 21: Diploid rates versus GA. Diploid rates for chromosomes 13 (A), 18 (B), 21 (C), and
X/Y (D) were compared with GA at time of sampling, using Spearman’s rho correlation. There
were no correlations for diploid rates and GA for all chromosomes examined.
On average, the total number of maternal cervical cells evaluated from 20 patients for
chromosomes 13, 18, 21, and X/Y were 30.5 ± 3.1, 36.2 ± 3.9, 30.9 ± 3.2, and 35.5 ± 7.8 cells,
respectively. The diploid rates for the maternal cervical cells for chromosomes 13, 18, 21, and
X/Y were 97.4% ± 0.53%, 94.8% ± 0.7% 96.3% ± 0.68%, and 97.2% ± 0.75%. There was no
significant difference in the diploid rates for chromosomes 13, 18, 21, and X/Y between EVT
cells isolated by TRIC and maternal cervical cells (Table 17).
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Table 17. Diploid rates for isolated EVT cells and maternal cervical cells
Percent Diploid
Chromosome 13

Percent Diploid
Chromosome 18

Percent Diploid
Chromosome 21

Percent Diploid
Chromosome X/Y

EVT Cells

95.4% ± 2.3%

93.4% ± 2.38%

88.1% ± 1.96%

97.8% ± 0.57%

Maternal Cells

97.4% ± 0.53%

94.8% ± 0.7%

96.3% 0.68%

97.2% ± 0.75%

Significance

NS

NS

NS

NS

Comparisons of diploid rates were performed with Mann-Whitney-Wilcoxon test, and significance was considered
p< 0.05. NS, not significant.

Discussion
These findings confirm that trophoblast cells from the endocervical canal can be isolated
using TRIC with a high degree of purity. Ideally, purity of TRIC samples is best evaluated by
the percentage of cells staining positive for the Y chromosome from known male fetuses. In this
cohort of 27 patients with known male fetuses, the percentage of cells staining for X/Y
chromosomes was 96.9%, which was similar to the purity determined by β-hCG staining at
94.2%, validating β-hCG staining as an accurate measurement of purity. These results are
consistent with a previous report that TRIC isolates EVT cells with a high degree of purity and
accurately predicts gender [68].
The low rates of mosaicism that were found in EVT cells are comparable to CVS [145].
Other studies of trophoblast cells isolated from the cervix of ongoing pregnancies are in
agreement with this study [63, 64, 173].

A potential problem in using trophoblast for

chromosome analysis is confined placental mosaicism (CPM).

CPM is characterized by

aneuploidy confined to the trophoblast lineage, occurs in approximately 1%-2% of fetuses, and is
associated with a high incidence of IUGR [174]. Additional studies are needed to fully evaluate
whether CPM occurs in a large number of EVT cells isolated by TRIC. Evidence of CPM was
found for several specimens when chromosome 21 was examined. In four specimens, where at
least 20 cells were assessed, the diploid rates ranged between 36%-60%, due primarily to trisomy
21.

It is interesting that only trisomy 21was observed in the small number of specimens
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examined, since this is one of the more survivable aneuploidies.
The aneuploidy rates in EVT cells found in this study differ significantly from previously
published results of one group and rather confirm with expected rates of CPM. Weier et. al. [70,
71] obtained rates of over 90% when analyzing aneuploidy in EVT cells by FISH for over 10
chromosomes. However, a large portion of the cells examined by Weier et. al. were obtained
using an in vitro model of cytotrophoblast differentiation along the invasive pathway, which
could have caused the anueploidy. Because the EVT cells obtained by TRIC were not cultured,
they more closely represent the cells in vivo. These are a unique group of trophoblast cells never
previously examined in large numbers as a pure population.
The ability of TRIC to efficiently isolate fetal EVT cells with a high degree of purity
from endocervical specimens of ongoing pregnancies as early as 5 weeks GA could provide the
earliest approach for PGD. Additionally, TRIC provides intact fetal cells, which could be used
to evaluate the entire fetal genome. This study, for the first time, establishes low rates of
aneuploidy in EVT cells isolated by TRIC, which lays the foundation for further development of
TRIC for PGD. Future studies evaluating FISH or comparative genomic hybridization (CGH)
results from patients with known aneuploidy will help to further evaluate TRIC as a clinically
useful tool for PGD.
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CHAPTER VII
TROPHOBLAST RETRIEVAL AND ISOLATION FROM THE CERVIX (TRIC) FOR
NON-INVASIVE FIRST TRIMESTER FETAL GENDER DETERMINATION IN A
CARRIER OF CONGENITAL ADRENAL HYPERPLASIA
Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal recessive defect in cortisol
biosynthesis. The incidence of the classical form of CAH is approximately 1:15,000 live births,
with a higher risk in certain populations such as Yupik Eskimos, where the frequency is as high
as 1:282 [175]. Clinical consequences arise from both failure to synthesize hormones in the
adrenal cortex, downstream of the enzymatic deficiency, as well as consequences from cortisol
precursor accrual [176]. Faulty conversion of 17-hydroxyprogesterone to 11-deoxycortisol by
the enzyme steroid 21-hydroxylase (21-OHD) is attributed to more than 95 percent of CAH
cases, and results in decreased cortisol synthesis [177]. 21-OHD is also responsible for the
conversion of progesterone to deoxycorticosterone in the synthesis pathway of aldosterone.
Phenotypes vary depending on the extent of 21-OHD impairment, with the most severe salt
wasting form causing hyponatremia, hyperkalemia, hypovolemia, and even death if left untreated
[178]. Decreased cortisol levels raise adrenocorticotropin hormone levels, resulting in overproduction and accumulation 17-hydroxyprogesterone (17-OHP). 17-OHP is then shunted to the
intact androgen pathway, where 17,20-lyase enzyme converts it to androgens. High androgen
levels cause genital ambiguity and external genital masculinization in newborn females, and
gradual postnatal virilization in either sex, unless treated [179, 180]. Screening for CAH is
highly effective in distinguishing the salt-wasting form to decrease mortality [181].
Dexamethasone treatment in utero should be introduced early in gestation to preclude
virilization of an affected female fetus. Treatment preferably needs to be introduced by 5–6
weeks of gestation unless a karyotype of 46,XY is obtained [182]. Delaying steroid intervention
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until the karyotype is obtained through conventional prenatal diagnostic approaches would not
benefit a female fetus.
Prenatal management of CAH is required because masculinization of external genitalia
begins at about 7 weeks gestational age [175].

Early repression of fetal pituitary

adrenocorticotropic hormone levels will avert virilization of the female fetus. Molecular genetic
analysis of fetal DNA acquired by amniocentesis or CVS is used to diagnose CAH deficiency in
utero [175]. Preimplantation genetic diagnosis provides an option for diagnosis of fetal CAH in
couples known to be carriers for the disease [183]. However, this approach requires in vitro
fertilization, which is not available to all couples due, in part, to high cost. Additionally, many
couples that are carriers for CAH, naturally conceive, and, therefore, require prophylactic
administration of dexamethasone.
We present a unique case in which prenatal gender testing by a novel, non-invasive
approach was used in the seventh week of pregnancy to correctly identify a male fetus of parents
who are both carriers for a mutation in 21-OHD, and previously had a child with CAH. Fetal
EVT cells were obtained at 7 weeks GA by using TRIC, as previously described [68].
Case report
A 25 year old Gravida 2 Para 1001, seen at the University clinic for an infertility work
up, had an unremarkable gynecological history with regular menses and menarche starting at 16
years of age.

Her medical history included kidney stones that required lithotripsy and

esophageal dilatation for a stricture.

Her obstetrical history included a previous normal

spontaneous vaginal delivery that was diagnosed with CAH. Genetic analysis of the parents
revealed a maternal 30 Kb deletion of CYP21A2 and a paternal mutation of Exon 1,5’end c.57
G>A (W19X). During the patient’s work up she was also found to be a carrier of the Fragile X
Syndrome with a premutation CGG repeat observed: 32,55. Her husband, who underwent a
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vasectomy in 2010, had a successful microsurgical epididymal sperm aspiration procedure that
produced adequate sperm for in vitro fertilization by intracytoplasmic sperm injection. The
patient underwent ovarian stimulation, and 15 oocytes were retrieved for in vitro fertilization.
Seven embryos had adequate maturation, and prior to embryo transfer, the patient underwent
preimplantation genetic diagnosis. Two male embryos without evidence of the 30 kb deletion of
the 21 –OHD gene were transferred on day 5. A positive β-hCG was obtained, and an ultrasound
examination at 7 weeks documented positive cardiac activity. At that time, fetal gender was
analyzed by TRIC, using an endocervical specimen obtained from the patient.
Materials and Methods
Endocervical sampling
The Institutional Review Board of Wayne State University approved the study, with
written informed consent obtained from the patient prior to participation. Endocervical sampling
was conducted, as described previously [58]. Briefly, the cervical specimen was collected with a
ThinPrep kit (Hologic, Inc., Marlborough, MA), using a cytobrush. The cytobrush was rinsed
into 20 mL of PreservCyt (Hologic) fixative solution, acidified to dissolve mucous, and
centrifuged at 400 x g for 5 minutes at 4°C. The supernatant was removed and the cell pellet was
re-suspended in 20 ml of ice-cold sterile PBS. Specimens were then washed by centrifugation
and re-suspended two more times in 20mL PBS. The final wash was brought to 10mL with PBS
at 4°C.
Immunomagnetic isolation of trophoblast cells
The processed endocervical cells were centrifuged and suspended in 1.5 mL PBS,
combined with anti-HLA-G-coupled nanoparticles (Clemente Associates), and incubated
overnight at 4°C with mixing.

The non-bound cells were collected after magnetic

immobilization of HLA-G-positive trophoblast cells.

A small aliquot of the isolated cell
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suspension was removed and counted to determine the number of cells recovered in the isolate.
Isolated HLA-G-positive cells were suspended in groups of approximately 50 cells in 200 mL of
PBS and centrifuged onto slides using a Shandon Cytospin 3 cytocentrifuge at 1500 RPM for 5
minutes. The purity of isolated trophoblast cells was determined by immunofluorescence for βhCG. The percent β-hCG-positive cells were quantified, using FITC-conjugated secondary
antibodies with a DAPI nuclear counterstain, as previously described [58].
FISH
Isolated trophoblast cells were analyzed at the Detroit Medical Center Cytogenetics
Laboratory by FISH, using the AneuVysion kit (Abbott Molecular), according to the
manufacturer’s protocol. Briefly, the slides were immersed in 0.11 mg/ml pepsin in 0.01 N HCl
for 10 min at 37±1ºC. Slides were then washed once in PBS for 5 minutes at room temperature,
and fixed with 1% formaldehyde for 5 minutes at room temperature. Slides were then washed in
PBS for 5 minutes at room temperature, and dehydrated serial immersion into 70%, 85%, and
100% ethanol at room temperature for 1 minute each. Slides were allowed to dry completely,
and were hybridized with AneuVysion probe sets (3 µl of each probe) at a denaturation
temperature of 75ºC for 5 minutes, followed by hybridization at a temperature of 37ºC for 16-20
hours. Slides were washed in 0.4X SSC containing 0.3% NP-40 at 73±1ºC for 2 min, then
2XSSC/0.1%NP-40 at room temperature for 2 minutes. Cells were counterstained with 3 µl of
DAPI. Using an Olympus BX51 epifluorescence microscope equipped with a 120-watt OEX
bulb, slides were analyzed using dual orange/green bandpass, single aqua bandpass, and DAPI
bandpass filters. Number of signals for chromosomes 18, X, and Y, were then counted and
recorded for each cell.
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Results
Isolation and purity of trophoblast cells
A total of 1400 trophoblast cells were recovered after immunomagnetic isolation. To
establish that the isolated cells were trophoblasts, immunofluorescence microscopy was used to
examine expression of β-hCG.

The percentage of cells expressing β-hCG among the

magnetically bound cells was 100% (17/17).
Gender determination using isolated trophoblast cells
Cells spun onto slides were submitted for FISH analysis to evaluate the number of X and
Y-chromosomes per cell. FISH analysis confirmed both X and Y-chromosomes in 18 out of 18
cells examined, consistent with a normal male gender (Figure 22).
Figure 22: FISH for X and Y
chromosomes in trophoblast cells
obtained by TRIC at 7 weeks of
gestation. Trophoblast cells were
labeled with probes for YP11.1q11.1 with spectrum orange for the
Y chromosome, for Xp11.1-q11.1
with spectrum green for the X
chromosome, and for 18p11.1q11.1 with spectrum aqua for
chromosome 18. Nuclear chromatin
is labeled with DAPI (blue).
Examples of six labeled cells are
shown. (scale bar = 25 μm)
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Discussion
Prenatal diagnosis of CAH is of clinical consequence because in utero treatment is
available to circumvent virilization of an affected female fetus. Therefore, in families with a
history of CAH, PGD is recommended.

Historically, prenatal diagnosis of CAH required

analyses of fetal genomic DNA obtained by invasive methods, using either CVS or
amniocentesis, which at earliest could be performed at 10 and 15 weeks of gestation,
respectively, and carries an approximately 0.5% risk of fetal loss [44]. Androgen excess can
virilize a female fetus as early as 6-7 weeks of gestation, so prenatal dexamethasone treatment
prior to obtaining prenatal testing has proven an effective method in limiting the effects of
virilization in female fetuses [178]. Dexamethasone, a potent steroid, has side effects for the
mother, including excessive weight gain, hyperglycemia, and severe striae [184]. The safety of
this procedure for children treated in utero remains controversial regarding future cognitive
functions [185, 186]. It is important to discontinue therapy as soon as possible in pregnancies
with a male fetus or an unaffected female fetus. However, waiting until amniocentesis or CVS
would cause mothers of unaffected offspring to be treated for an extra 6-8 weeks [187]. Due to
autosomal recessive inheritance patterns, parents with heterozygous mutations carry a 1 in 8 risk
of an affected female fetus. Mothers who undergo prenatal dexamethasone treatment will be
unnecessarily treated seven of eight times [188].
Cell-free fetal DNA obtained from maternal plasma offers a promising non-invasive
approach that relies on complex bioinformatics to distinguish small fragments of fetal DNA from
a much greater fraction of maternal DNA [189]. Recently, this method has been used in the
detection of 21-hydroxylase deficiency; however, it is not commercially available prior to ten
weeks GA [190]. Additionally, it would be advantageous to acquire the entire genome by noninvasive collection of intact fetal cells for more reliable genetic testing.
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Trophoblast cells accumulate in the endocervical canal, and can be recovered by a
number of methods [49]. Multiple investigators have attempted to use these cells for prenatal
genetic diagnosis. However, the approach has been limited by the inability to efficiently separate
the fetal cells from the excess of maternal cervical cells. By making use of HLA-G, a protein
present on trophoblast cells and not on maternal cervical cells [150], we have demonstrated the
ability to isolate trophoblast cells from their maternal contaminants with a high degree of purity
[68]. Additionally, we have shown that on average 912 trophoblast cells with a high degree
(99%) of purity and intact fetal DNA from ongoing pregnancies can be isolated. Furthermore,
gender identification by both FISH and PCR is reliable as early as 5 weeks of GA [68], which
could benefit a large portion of pregnancies threatened with CAH that carry a male fetus. In this
case report, we isolated 1400 intact trophoblast cells at 7 weeks GA with a high degree of purity
based on both β-HCG staining and FISH determination of an XY genotype to correctly identify
male gender. This case report introduces a novel non-invasive approach for early prenatal
determination of fetal gender in pregnancies at risk for CAH, and demonstrates the potential for
TRIC to serve as an approach to allow early gestational identification of genomic identifiable
disorders.
Conclusion
Trophoblast cells accumulating in the endocervical canal offer a novel approach for noninvasive prenatal gender testing by TRIC as early as 5 weeks GA. TRIC was used for gender
testing at 7 weeks GA in a pregnancy conceived by carriers of CAH.
confirmed by FISH.

Male gender was

Gender determination by TRIC would benefit patients at risk for

transmitting genetic mutations related to CAH who do not have access to preimplantation genetic
diagnosis, or conceived naturally. Early determination of male fetal gender would prevent
unnecessary use of exogenous steroids. Because TRIC isolates cells with an intact fetal genome,
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it could potentially be used for diagnosis of genetic mutations such as CAH, benefiting the
remaining pregnancies that would otherwise receive and unneeded intervention. Due to the ease
of performing TRIC, this approach could benefit populations lacking access to advanced
reproductive technologies. The isolation of intact trophoblast cells by TRIC will eventually
provide opportunities for fetal whole genomic sequencing, as well as targeted gene analysis, as
early as 5 weeks GA.
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CHAPTER VIII
CONCLUSION AND FUTURE DIRECTION
The overall goal of this translational study was to investigate the potential of TRIC for
preclinical evaluation of adverse pregnancy outcomes, and its use for PGD. We have confirmed
that TRIC provides a homogenous population of EVT cells that exhibit altered protein signatures
in pregnancies with adverse outcomes due to abnormal placentation. Furthermore, EVT cells
obtained by TRIC exhibit low rates of mosaicism, laying the foundation to develop TRIC for
PGD.
TRIC is currently the only available method capable of obtaining useful intact placental
cells in a non-invasive fashion from ongoing pregnancies. Using TRIC, we demonstrated the
altered expression of six proteins known to play a role in trophoblast function in pregnancies
with placenta-related disorders. It is interesting that despit the location of EVT cells in the
endocervical canal, far from the anchoring villi and placental bed, theu protein profile remians
consistent with the EVT phenotype [68], and reflects the pathophysiology of the corresppnding
placenta. Further studies are needed to determine how accurately this group of trophoblast cells
reports placental pathology. I anticipate that it would be fruitful to evaluate EVT cells obtained
by TRIC for expression of EGF family proteins, as EGF, HBEGF, and TGFA expression are all
downregulated in post-partum placentas from patients with preeclampsia. Additionally, TRIC
can potentially be used for comparative analysis of EVT cells by transcriptomics and proteomics
in women with healthy and adverse pregnancy outcomes, which could reveal novel biomarkers
and therapeutic options for placenta-related pregnancy disorders.

Growing evidence links

placental epigenetic modifications with adverse pregnancy outcomes [191].

Thus, TRIC

provides a unique approach by which placental epigenetic changes could be studied in real time.
EVT dysfunction in early pregnancy has also been linked to PTL. PTL affects approximately
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5%-18% of pregnancies and growing evidence links EVT dysfunction to PTL [5]. In addition to
PE, IUGR, and EPL, TRIC could be used to evaluate pregnancies at risk for PTL.
One of the difficulties in studying PE is the lack of a proper animal model that reflects
the etiology found in humans. PE induced in animal models is not comparable to humans, and
cannot be generated by dysregulated EVT function [192].

Live EVT cells obtained by

modifying TRIC to eliminate cell fixation could provide, for the first time, immortalized cell
lines from patients to model PE or other perinatal diseases. A PE cell line could be used to gain
better insight onto the molecular mechanisms associated with PE in humans, and to study
therapeutic options.
The low rate of mosaicism found by FISH analysis of EVT cells isolated from the cervix
lays the foundation for TRIC to be developed as a method for PGD. TRIC specimens from
patients with known aneuploidies will be needed to assess the ability of TRIC to detect
aneuploidies. Although FISH is a reliable method for PGD, TRIC evaluation of the entire fetal
genome as early as 5 weeks GA from ongoing pregnancies could be possible by using
comparative genomic hybridization [193] or next-generation sequencing [189] approaches.
The pre-clinical prediction of pregnancies at risk for adverse outcomes could not only
impact patient care, but would also decrease healthcare costs by channeling resources away from
low-risk pregnancies and towards pregnancies at risk for adverse outcomes. Using TRIC to
identify women at risk for adverse pregnancy outcomes in the first trimester would allow
investigators to target proposed disease interventions to subjects with very high probability for
disease, and, thus, determine efficacies with smaller patient cohorts. Lastly, the relatively low
cost of TRIC can provide PGD and screening for adverse pregnancy outcomes in third world
countries with limited healthcare resources, and bring these services to a wider range of patients
in developed nations.
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The placenta is vital for the short- and long-term health of the fetus, and significantly
impacts the health of the mother.

During the first and second trimesters of pregnancy,

extravillous trophoblast (EVT) cells invade the uterus and remodel the maternal spiral arteries
which, if inadequate, lead to pregnancy complications, including early pregnancy loss (EPL),
preeclampsia (PE), and intra-uterine growth restriction (IUGR). EVT migration into the uterine
wall is dependent on growth factors and cytokines that signal between maternal and fetal tissues.
The epidermal growth factor (EGF) signaling system plays a significant role in trophoblast
survival and function. Using immunocytochemistry (ICC), we evaluated EGF family growth
factors in post-partum PE placentas (villi and basal plate), and maternal serum, comparing to
placentas to gestational age (GA)-matched preterm pregnancies, IUGR pregnancies, and
uncomplicated term pregnancies. EGF, heparin-binding EGF-like growth factor (HBEGF), and
transforming growth factor alpha (TGFA) were significantly decreased in placentas from PE
compared to IUGR, preterm labor, and uncomplicated term placentas. It was uncertain whether
reduced growth factor signaling contributed to disease, or was the result of late-stage pathology.
However, EGF was significantly reduced in prenatal serum of pregnant patients with PE
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compared to GA-matched patients without PE, demonstrating that the EGF signaling system is
disrupted before PE symptoms dictate delivery.
Currently, chorionic villous sampling is the only means by which intact placental cells
can be obtained from an ongoing pregnancy. However, the earliest this invasive procedure can
be performed is 10 weeks GA, and it carries a risk of fetal loss. Trophoblast retrieval and
isolation from the cervix (TRIC) can isolate intact trophoblast cells in a minimally invasive
procedure from ongoing pregnancies as early as 5 weeks GA, using immunomagnetic isolation to
target human leukocyte antigen-G, a protein present on trophoblast cells, but not on maternal
cervical cells. ICC shows that the isolated cells are of the extravillous phenotype. The ability to
isolate EVT cells from ongoing pregnancies not only provides clinicians with a tool to study the
placenta in real time, but is also of benefit for prenatal genetic diagnosis (PGD). EVT protein
expression was investigated, using TRIC with patient specimens obtained between 5-20 weeks
GA. Using ICC, galectin 13 (LGALS13), galectin 14 (LGALS14), pregnancy-associated plasma
protein-A (PAPPA), placental growth factor (PGF), endoglin (ENG), fms-like tyrosine kinase-1
(FLT1), and alpha-fetoprotein (AFP), proteins known to play a role in EVT function, were
evaluated in EVT cells from patients that developed PE, IUGR, or EPL, and compared to
pregnancies with uncomplicated term deliveries. Expression of LGALS14, PAPPA, and PGF
significantly decreased in EVT cells from patients that developed IUGR, PE, or EPL, whereas
expression of ENG, FLT1, and AFP were all significantly increased.
To evaluate the potential of TRIC for PGD, aneuploidy rates in EVT cells were studied in
pregnancies with a diploid fetus, using fluorescent in situ hybridization (FISH). Diploid rates for
chromosomes 13, 18, 21, and X/Y were 95.4 ± 2.3%, 93.4 ± 2.38%, 88.1± 1.96%, and 97.8±
0.57%, respectively. The percentage of EVT cells with a normal X/Y genotype in the cohort of
EVT cells obtained from confirmed male fetuses was 96.9% ± 1.5%, confirming that TRIC
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isolates a homogenous population of EVT cells, free of maternal cells.

Diploid rates for

maternal cervical cells and fetal EVT cells were not significantly different.

Interestingly,

trophoblast yield by TRIC was unaffected by GA, maternal obesity, parity, or maternal age,
further highlighting the advantages of TRIC over other approaches for PGD. Finally, TRIC was
used successfully for gender determination at 7 weeks GA in a case study of a pregnancy in
which both parents were carriers of congenital adrenal hyperplasia (CAH). Early identification
of male fetuses with TRIC PGD could eliminate the need for unnecessary prophylactic
administration of high-dose dexamethasone prenatally to prevent the virilization of a female
fetus.
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